Cholesterol 7 .alpha.-hydroxdylase gene regulatory elements and transcription factors

Abstract

DNA regulatory elements that control cholesterol 7.alpha.-hydroxylase expression are disclosed, including bile acid responsive elements. A gene construct comprising at least one CYP7 regulatory element and a reporter gene is used to transfect HepG2 cells. Confluent transfected HepG2 cells are employed in an assay to detect a compound that modulates cholesterol 7.alpha.-hydroxylase enzyme regulation. A method for screening compounds that inhibit or stimulate expression of the enzyme is provided, as well as a method for detecting and isolating transcription factors of the cholesterol 7.alpha.-hydroxylase gene. A transcription factor of 57 KDa is identified which is useful in an assay for determining regulation of CYP7 expression.

Description

Work related to subject matter described in this application was provided by research supported in part by NIH Grant GM 31584.

BACKGROUND OF THE INVENTION

High serum cholesterol is commonly associated with an increased risk of heart attack, atherosclerosis and circulatory disorders. In addition, a variety of diseases are caused by disorder of cholesterol catabolism, such as gallstone disease, atherosclerosis, hyperlipidemia and some lipid storage diseases.

The major pathway for disposal of cholesterol in the body is by secretion of cholesterol and bile acids into the gut. Bile contains free cholesterol and bile acids. The enzyme, cholesterol 7.alpha.-hydroxylase (CYP7) commits cholesterol to bile acid synthesis and catalyzes the first and rate-limiting step of bile acid synthesis in the liver. Thus, by increasing synthesis of bile acids, this enzyme plays a key role in the liver by depleting hepatic cholesterol pools, resulting in increased LDL uptake and a lowering of serum cholesterol levels.

Bile acids are physiological agents which are important in the solubilization of lipid-soluble vitamin, sterol and xenobiotics. Bile acids are synthesized exclusively in the liver and are secreted to the intestines where they are modified to secondary bile acids. Most bile acids are reabsorbed in the ileum and recirculated to the hepatocytes via the portal vein.

The feedback of bile into the liver is known to inhibit cholesterol 7.alpha.-hydroxylase and thus inhibit the overall rate of bile acid synthesis. Cholesterol 7.alpha.-hydroxylase therefore has been a subject of intense studies to elucidate the regulatory mechanisms of bile acid synthesis in the liver.

It is known that an interruption of bile acid reabsorption, such as caused by the bile sequestrant, cholestyramine, or by a bile fistula, stimulates the rate of bile acid synthesis and cholesterol 7.alpha.-hydroxylase activity in the liver. It is believed that cholesterol 7.alpha.-hydroxylase activity in the liver is regulated primarily at the gene transcriptional level by bile acids cholesterol, hormones, diurnal rhythm and other factors.

Generally, the regulation of eukaryotic genes is thought to occur at several locations, including the promoter sequences, located upstream of the transcription start site; enhancer or repressor sequences, located upstream of the promoter; within intron sequences, non-coding sequences located between exons or coding sequence; and in 3' sequences, located downstream from the coding region. The promoter sequence is unique to each gene and is required for the accurate and efficient initiation of gene transcription. Enhancers and/or repressors regulate promoter activity and determine the level of gene transcription during development and differentiation of a particular tissue.

The promoter of most eukaryotic genes contains a canonical TATA box which binds a TFIID TATA box binding protein. TFIID complex and associated transcription activators (TAFs) interact with the basal initiation factors and RNA polymerase II to activate promoter. The transcription complex assembly and initiation are regulated by transcription factors bound to enhancer elements located in the promoter and other regions of the gene (Pugh and Tjian, J. Biol. Chem. 267, 679-682, 1992). Tissue-specific transcription factors and nuclear steroid hormone receptors are known to play an important role in the regulation of gene expression in different tissues during development and differentiation.

However, the mechanisms underlying the regulation of cholesterol 7.alpha.-hydroxylase CYP7 gene expression at the molecular level are not understood. An understanding of regulation of CYP7 gene expression would permit development of therapeutics for treating patients with defects in bile acid synthesis and cholesterol metabolism due to altered (deficient or excessive) gene expression.

In order to study the mechanism of regulation of human cholesterol 7.alpha.-hydroxylase at the molecular level, it is therefore important to determine the correct gene sequence of its coding and promoter regions. An elucidation of its gene structure and its promoter/enhancer activity is sought in order to assay for an agent that modulates cholesterol 7.alpha.-hydroxylase enzyme regulation.

Beyond knowledge of the promoter sequence, a cell line is sought that is suitable for transfecting with a CYP7 regulatory element/reporter gene construct to determine the regulatory activity of a particular promoter region. Such a cell line then could be employed in a method for screening compounds for inhibiting or stimulating CYP7 expression by its direct or indirect interaction with the regulatory region, as reported by the reporter gene.

A method for detecting and isolating the CYP7 transcription factors also is sought. Further, upon determining a transcription factor, an assay is desired to discover other endogenous factors or exogenous agents that interact directly or indirectly with the transcription factor. Such an assay is useful to determine factors or agents that modulate the activity of the transcription factor and thereby affect expression of cholesterol 7.alpha.-hydroxylase protein.

SUMMARY OF THE INVENTION

An embodiment of the invention provides a DNA sequence that comprises at least one regulatory element of cholesterol 7.alpha.-hydroxylase expression. In an advantageous embodiment, the DNA sequence comprises at least one regulatory element of cholesterol 7.alpha.-hydroxylase expression in either rat, human or hamster.

Another embodiment of the invention provides a rat CYP7 promoter region, deposited as clone R7.alpha.B24 on Jan. 28, 1994, at the American Type Culture Collection, ATCC, 12301 Parkland Drive, Rockville, Md. 20852, U.S.A., under accession number ATCC 69546.

An advantageous embodiment provides a DNA sequence comprising a regulatory element of a CYP7 gene which is selected from DNA fragments in the group consisting of human CYP7 gene fragments from about -158 to about +32, from about -3643 to about -224, and from about -223 to about +32; and rat CYP7 gene fragments in the group consisting of from about -160 to about +32, from about -3643 to about -224, and from about -224 and +32.

Another embodiment provides a DNA sequence comprising a regulatory element of the cholesterol 7.alpha.-hydroxylase (CYP7) gene selected from DNA fragments in the group consisting of from about -191 to +64 (SEQ ID NO: 25) of the rat CYP7 gene, from about -252 to +3 (SEQ ID NO: 26) of the hamster CYP7 gene and from about -187 to +65 (SEQ ID NO: 27) of the human CYP7 gene, or functionally active parts thereof.

Another advantageous embodiment provides DNA selected from fragments of DNA identified in Table 1, columns 1-3.

Another advantageous embodiment of the invention provides a gene construct containing at least one of the foregoing regulatory elements and a reporter gene.

Another embodiment provides a method for determining whether an agent inhibits or stimulates CYP7 gene expression. Yet other embodiments provide methods for detecting, substantially isolating and using in an assay a transcription factor of the cholesterol 7.alpha.-hydroxylase gene.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates the rat CYP7 gene map. Boxes indicate exons. The arrows indicate the region for which a nucleic acid sequence of clone R7.alpha.B24 (shown in FIGS. 8(A)-8(E)) now is determined.

FIGS. 2A, 2B and 2C provide maps of the human CYP7 gene and clones .lambda.HG7.alpha.26 and .lambda.HG7.alpha.5. FIG. 2A shows the gene map of human CYP7. FIG. 2B shows the gene map of the .lambda.HGY.alpha.26 clone. FIG. 2C shows the gene map of the .lambda.HG7.alpha.5 clone. Heavy boxes represent exons I, II, and III. The arrows indicate regions for which nucleic acid sequences now are determined. These sequences are shown in FIGS. 9, 10 and 11 (SEQ ID NOS 32, 33 and 34 respectfully).

FIG. 3 illustrates the hamster CYP7 gene map. The arrows indicate the region for which a sequence (shown in FIG. 12 SEQ ID NO: 35) now is determined.

FIG. 4 shows an alignment of the proximal promoter regions of rat, human and hamster CYP7 genes (SEQ ID NOS 25, 27 and 26 respectfully). The following abbreviations are used: GRE, glucocorticoid response element; LFA1, liver factor 1; HRE, steroid/thyroid hormone response element; PPRE, peroxisome proliferator response element; TGT3, TGT3 element; and LFB1, liver factor B1. Transcription start sites "G" are indicated by a "*". Translation start codons "ATG" are underlined. The numbers indicate the nucleotide positions in each gene.

FIG. 5 shows a diagram indicating the positions at which transcription factors bind to the CYP7 proximal promoter. The following abbreviations are used: HNF, hepatocyte nuclear factor; TRE, thyroid hormone response element; C/EBP, liver specific enhancer binding protein; and TFIID, TATA box binding site representing general transcription complex.

FIG. 6 shows the DNase I hypersensitivity sites (I, II, III and IV) in the SacI fragment of the rat CYP7 gene. Heavy boxes are exons. A 5'-probe was used for hybridization.

FIGS. 7A, 7B and 7C (SEQ ID NOS 28, 29 and 30 respectfully) show the amino acid sequences of human, rat and hamster CYP7. FIG. 7A shows the human amino acid sequence, FIG. 7B shows the rat amino acid sequence and FIG. 7C shows the hamster amino acid sequence.

FIGS. 8(A)-8(E) show (SEQ ID NO: 31) the nucleotide sequence of the region of the rat CYP7 gene taken from deposit R7.alpha.B24 and indicated by arrows in FIG. 1. The transcription start site "G" is located at nucleotide position 3644. Exon I (3644-3784), Exon II (5400-5640), Exon III (6348-6934) and Exon IV (7928-7997).

FIG. 9 (SEQ ID NO: 32) shows the approximately 5.5 kb nucleotide sequence of the .lambda.HG7.alpha.26 clone indicated by arrows in FIG. 2B.

FIG. 10 (SEQ ID NO: 33) shows the approximately 2.6 kb nucleotide sequence of the .lambda.HG7.alpha.26 clone indicated by arrows in FIG. 2B.

FIG. 11 (SEQ ID NO: 34) shows the approximately 2.3 kb nucleotide sequence of the .lambda.HG7.alpha.5 clone indicated by arrows in FIG. 2C.

FIG. 12 (SEQ ID NO: 35) shows the nucleotide sequence of the region of the hamster CYP7 gene indicated by arrows in FIG. 3.

FIG. 13 shows the effect of bile acid conjugates on the expression of cholesterol 7.alpha.-hydroxylase mRNA levels in confluent (striped block) and subconfluent (solid block) cultures of HepG2 cells, determined by Northern blot hybridization as described in Example 3.3. The endpoint of the sequenced promoter region terminates at position -3643, while the full length of this sequence rat clone is 7997 (SEQ ID NO: 35) total nucleotides long.

FIG. 14 shows the effect of promoter (observed in control cells), or of added thyroxine (T.sub.4) and dexamethasone (Dex) on the transcriptional activity of cultures of confluent (A) or subconfluent (B) HepG2 cells, transiently transfected with CYP7/LUC constructs.

FIG. 15 shows the effect of bile acids on transcriptional activity of CYP7/LUC constructs transiently transfected into cultures of confluent (A) or subconfluent (B) HepG2 cells, as described in Example 3.5.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

It was found, surprisingly, that DNA fragments comprising nucleotides downstream from about -187 (SEQ ID NO: 27) of the human CYP7 gene, downstream from about -191 (SEQ ID NO: 25) of the rat CYP7 gene, and downstream from about -252 (SEQ ID NO: 26) of the hamster CYP7 gene are regions that exert regulatory control of transcription of the human, rat and hamster CYP7 gene, respectively.

In particular, it was found that a bile acid responsive element is located within a fragment between nucleotides -160 and +32. According to the invention, a second bile acid responsive element is located in the region between nucleotides -3643 and -224. This was shown by transfecting hepatoma Hep2G cells with promoter/reporter constructs that contain these genetic elements within the promoter region of the construct. Thereafter the transfectants were exposed, for example, to bile acids taurodeoxycholate ("TDCA") and taurochenodeoxycholate ("TCDCA") and transcriptional activity of the reporter gene was repressed. More specifically, transcriptional activity in HepG2 cells transfected with construct pLUC-3600 was repressed by about 75%. When transfecting with pLUC-224 or pLUC-160, the transcriptional activity was repressed by about 45% or about 35% respectively, (FIG. 15(A)).

Advantageously, a fragment located in the region between -160 and +32 was pinpointed to interact with at least one BARP. This fragment specifically is a direct repeat without spacing, and hence was designated as "DR.sub.0 ". DR.sub.0 in the rat is (SEQ ID NO: 36) TCAAGTTCAAGT, and correspondingly in the human, is (SEQ ID NO: 37) CCAAGCTCAAGT. DR.sub.0 is a bile acid responsive element (BARE) that binds to a bile acid responsive protein (BARP) factor in the nucleus of liver cells or its nuclear extracts. Accordingly, a consensus "core" nucleotide sequence that emerges from the two species of the molecule is (T or C)CAAG(T or C).

As described in Example 2.3 (b), gel shift experiments detect a BARP that binds or interacts with a bile acid responsive element 7.alpha.-TRE, for both human and rat, and human and rat DR.sub.0 element. This BARP was characterized and possesses a molecular weight of about 57,000 Daltons, with an experimental error of about .+-.7000 Daltons.

Additionally, a thyroid and steroid hormone responsive element is located between -3643 and -224 of the rat CYP7 gene. This was demonstrated by increased transcriptional activity of pLUC-3600 upon stimulation with 1 .mu.M T4 and 0.1 .mu.M dexamethasone by 2.5-fold in confluent cultures, as demonstrated by FIG. 14.

According to the present invention, the term "regulatory" means a characteristic ability of a DNA fragment to exert transcriptional control of a CYP7 gene in the presence of a factor that either down-regulates the CYP7 expression, e.g., bile salts or mevinolin, or up-regulates CYP7 expression, e.g., cholestyramine, bile fistula or cholesterol. Thus, a "regulatory element" refers to a DNA fragment disclosed in accordance with this invention that has regulatory activity with respect to CYP7.

Advantageously, an embodiment of the present invention provides a bile acid responsive element of a rat CYP7 gene which are selected from the group comprising DNA fragments from about -160 and about +32, and between about -3643 and about -224. A further embodiment comprises a bile acid responsive element of a CYP7 human gene which is selected from the group comprising fragments from about -158 to about +32, from about -3643 to about -224, from about -223 to about +32.

Another embodiment provides that a thyroid and steroid hormone responsive element within a fragment between about -3643 and about -224 of the rat CYP7 gene.

Another embodiment of the present invention provides a regulatory element of a CYP7 gene selected from the group comprising DNA fragments, from about -191 to about +64 of the rat CYP7 gene, from about -252 to about +3 of the hamster CYP7 gene and from about -187 to about +65 of the human CYT7 gene, and regulatory DNA fragments spanning a region within these fragments (subfragments), such as fragments shown in FIG. 4 (SEQ ID NOS 25, 26 and 27 respectfully).

Yet another advantageous regulatory element of the rat CYP7 gene is selected from the group of DNA fragments having regulatory activity and consisting of any of the eight fragments of DNA described in the first column of Table 1. The corresponding regulatory elements of hamster and human gene are closely homologous, as shown in FIG. 4 (SEQ ID NOS 25, 26 and 27 respectfully), and as listed in Table 1. Thus, an advantageous human CYP7 regulatory element is selected from the group consisting of any of the fragments of DNA described in the second column of Table 1 or human 7.alpha.-TRE, while an advantageous hamster CYP7 regulatory element is similarly selected from the group consisting of any of the eight fragments of column three of the Table 1. DNA fragments which begin at about the downstream nucleotides and end at about the upstream nucleotides as recited in Table 1 are also contemplated.

In addition to a regulatory element selected from the fragments described above (comprising from about -191 to about 64 (SEQ ID NO: 25) of the rat CYP7 gene, from about -252 to about 3 of the hamster CYP7 gene and from about -187 to about 65 of the human CYT7 gene, and fragments described in Table 1), it is contemplated that other substantially homologous sequences will have CYP7 regulatory activity and thus can be used as regulatory elements in accordance with this invention. Exemplary substantially homologous sequences include: substantially homologous sequences having at least about 80%, advantageously about 90% and more advantageously about 95% nucleotide sequence homology with respect to the described fragments; sequences having at least about 82%, and advantageously at least about 90%, homology between a pair of corresponding rat and hamster DNA sequences, such homology to the sequence from about -101 to about -29 of the rat CYP7 gene and the sequence from about -161 to about -86 of the hamster CYP7 gene, for example; and sequences having homology of at least about 71%, advantageously at least about 90%, between any pair of corresponding rat and human DNA sequences, for example, about -101 to about -29 of the rat CYP7 gene and the sequence from about -104 to about -30 of the human CYP7 gene.

TABLE 1______________________________________Regulatory elements of rat, human and hamsterCYP7 geneI. Rat II. Human III. Hamster(from transcript. start site) (from start codon)______________________________________-101 to -29 -104 to -30 -161 to -86-81 to -37 -78 to -36 -136 to -92-161 to -127 -159 to -124 -208 to -184-149 to -131 -147 to -128 -206 to -188-171 to -154 -169 to -152 -228 to -211-101 to -82 -104 to -79 -161 to -137-73 to -56 -71 to -54 -128 to -111-86 to -71 -89 to -68 -146 to -126-160 to +32 -158 to +32 ---224 to +32 -223 to +32 ---3643 to +32 -3643 to +32 --______________________________________

Further embodiments of the present invention include a recombinant construct comprising at least one of the above-mentioned regulatory elements, advantageously a fragment disclosed in Table 1. Advantageously, for example, a regulatory element can be operably attached to a structural gene encoding CYP7, or to a reporter protein. Operably attached means that the regulatory element is positioned with respect to the structural gene such that it exerts control of the transcription of the structural gene.

A construct according to the invention can be provided in a vector capable of transforming a host cell. A host cell transformed or transfected with such a vector also comprises an embodiment of this invention, as well as a method for expressing a selected structural gene, advantageously CYP7 or a reporter gene, using host cells of this invention. Such a method of expression comprises the steps of culturing a host cell transformed with a recombinant DNA vector comprising a gene construct comprising at least one regulatory element operably attached to the selected structural gene, wherein culturing is performed in a medium that is suitable for accommodating the desired expression, and producing the gene product.

A reporter gene allows quantitative determination of gene expression in the presence of inhibitory or stimulatory compounds. A host cell transformed with a recombinant DNA vector comprising a gene construct of at least one regulatory element operably attached to the selected structural gene provides an expression system useful in a conventional method to screen a compound for its ability to inhibit or stimulate structural gene expression. Thus, an example of a screening method provides contacting the host cell with a test compound and detecting an inhibition or stimulation of gene expression. A test compound can comprise, for example, a physiological agent derived from substances endogenous to a human or, an exogenous compound.

Regulatory elements, advantageously those fragments identified in Table 1, are used to control expression of structural genes, such as the CYP7 gene, and various reporter or indicator genes. Reporter genes include, but are not limited to, E. coli .beta.-galactosidase, galactokinase, interleukin 2, thymidine kinase, alkaline phosphatase, luciferase and chloramphenicol acetyltransferase (CAT). Those skilled in the art readily will recognize additional reporter genes.

A representative construct of regulatory element and reporter gene ("promoter/reporter construct") is made according to Example 2.6, which employs, for example, the rat regulatory element -101 to -29. Any of the other regulatory elements according to the invention, preferably those described in Table 1, can be substituted for that rat fragment -101 to -29, by using conventional genetic engineering methods.

According to the present invention, CYP7 constructs, such as the promoter/reporter construct, are transfected into a hepatoma cell line, advantageously, human hepatoma cell line HepG2. HepG2 liver cells express cholesterol 7.alpha.-hydroxylase normally, which makes these cells good candidates for the study of CYP7 regulation. Northern blots of normal HepG2 cells that were exposed to several bile acids, including tauro- or glyco-conjugates of cholate, deoxycholate, chenodeoxycholate or ursodeoxycholate, exhibited responsive changes in CYP7 mRNA levels as compared to non-responding control cell lines that were not exposed to those bile acids.

HepG2 cell lines are useful in screening methods provided according to the present invention. By observing expression of CYP7 in HepG2 cultures transiently transfected with CYP7 promoter/reporter gene constructs, the activity of a particular promoter region can be ascertained. Further, an agent can be added to the transfectant, and its effect on transcription can be ascertained readily.

More advantageously, a host HepG2 cell line according to the present invention that is transfected with promoter/reporter gene is both "confluent" and stable. Confluent cells are defined as cells that are at least about 4 days old, preferably 5 days, relative to the initiation of transfection. Confluent cell lines alternatively can be recognized by their uniform growth pattern, where cells tend to "adhere" to one another.

Preferably, stabilized HepG2 transfectants are employed in an assay according to the invention to provide more consistent results. A transfected cell line is stabilized using known methodology, as described by Dai et al., Biochem. 32:6928 (1993).

According to the present invention, it was discovered that the age of HepG2 transfectant cultures had a significant effect on the cells' response to steroid/thyroid hormones or bile acid conjugates. Both the endogenous cholesterol 7.mu.-hydroxylase mRNA and transcriptional activity of the CYP7 chimeric promoter/reporter gene constructs transiently transfected into HepG2 cells responded to hydrophobic bile acids in the adult phenotype only. Younger cells were much less responsive to hormones and produced no response to bile acids, possibly due to an underdeveloped or undeveloped bile acid transport system and/or an immature steroid hormone receptor system.

Results obtained by an assay method employing confluent HepG2 cells that were transiently transfected with rat promoter/reporter constructs according to the invention identified two regions in the CYP7 gene that are responsive to bile acid repression. One bile acid responsive element (BARE) is located in the highly conserved proximal region of the promoter, from nucleotide -160 to +36, while another BARE is located in the region between -224 to -3643.

The inventive regulatory elements are also useful for detecting and isolating a transcription factor of CYP7. To detect a transcription factor, a regulatory element according to the invention, advantageously an element from Table 1, is contacted with a biological sample suspected of containing a transcription factor. Binding between the fragment and a transcription factor and the step of isolating the transcription factor are accomplished by conventional methods.

For example, to isolate a transcription factor, the following steps can be employed. First, a footprinting assay is performed to determine whether a particular gene fragment, such as a regulatory element according to the invention, binds to a nuclear transcription factor. The footprinted sequence that is revealed is used to identify DNA-protein interactions by electrophoretic mobility assay (EMSA). If a band shift is detected in EMSA, the shifted sequence is confirmed by Southwestern blot. The Southwestern blot, by SDS-polyacrylamide gel electrophoresis separates nuclear proteins. A separated protein then is incubated with a shifted DNA sequence to identify a nuclear transcription factor. The DNA sequence then is used to screen an expression cDNA library for cDNA clones encoding a transcription factor. In an alternative method, a DNA fragment of the invention can be fixed to an affinity column and used to isolate a transcription factor present in nuclear extracts (See Example 2).

An identified transcription factor can be cloned and expressed in relatively high amounts and then employed in screening compounds for the ability to influence gene expression via the specific transcription factor. For example, the effect of a bile acid or its derivatives on the function of a BARP identified according to the invention is studied by a cotransfection assay. In this assay, a CYP7 promoter/luciferase construct according to the invention, advantageously pLUC-160 and an expression plasmid containing a BARP cDNA, are cotransfected into HepG2 cell cultures. Next, an investigator determines transcriptional activity of the chimeric gene constructs (by way of the reporter gene) in the presence of test agents or endogenous factors and in control cell lines. Additionally, HepG2 cells can be transfected with a BARP, so as to express it in high amounts. Then, EMSA and footprinting assays also are performed to study the activity of a BARP.

The following examples illustrate the invention and, as such, are not to be considered as limiting the invention set forth in the claims. Either human or hamster regulatory elements can be substituted for rat regulatory elements in the following examples.

EXAMPLE 1

CLONING AND NUCLEOTIDE SEQUENCING OF THE CYP7 GENES

1. (A) The Rat Gene

A rat genomic library (Clontech, RL1022j) was screened with a rat cholesterol 7.alpha.-hydroxylase cDNA previously isolated by Li et al., J. Biol. Chem. 265, 12012-12019, (1990). After screening about 1 million plaque-forming units (pfu), a positive clone, .lambda.R7.alpha.2 was plaque-purified. This clone contains a 13 kb insert that spans 8 kb of the 5'-flanking region as well as the transcription region covering exons 1 through 3 and a partial exon 4 (FIG. 1). The nucleotide sequencing of an 8 kb (SEQ ID NO: 31) SacI fragment is shown in FIGS. 8(A)-8(E) and includes the 3643 bp 5'-flanking region and coding region from exon 1 to exon 4. This fragment includes about 2 kb of the 5'-upstream region, the sequence of which was published recently by the inventor (Chiang, et al., Biochim. Biophys. Acta. 1132, 337-339, 1992). Many putative regulatory elements, including liver-enriched hepatic nuclear factors (HNFs) binding sites, steroid/thyroid hormone response elements, and ubiquitous transcription factor binding motifs (NF1, OTF-1), were identified in this gene fragment.

It was shown previously that high cholesterol diet up-regulates transcription of the cholesterol 7.alpha.-hydroxylase gene, translation of CYP7 mRNA, and increases enzyme expression and activity in rat liver (Li, et al. J. Biol. Chem. 265, 12012-12019, 1990). It is especially noteworthy that steroid regulatory elements (SREs) similar to those found in the LDL receptor, HMG-CoA reductase, and HMG CoA synthase genes are located in the upstream region of the rat CYP7 gene promoter. These SREs are not present in the human or hamster CYP7 gene promoter. These SRE's are -1222-ATCCTCTCCCCACTCCCAAGCATCCCTCCATG-1191 (SEQ ID NO: 1), -1151 -CAACTCCTCCCCTATT-1335 (SEQ ID NO: 2). Repeats 1 and 2 in the rat CYP7 gene are similar to the consensus SRE1 (CACC(C/G)(C/T)AC), which represses gene expression in the presence of oxysterols. The repeat 3 of the LDL receptor SRE has 11 bases identical to the sequence between -1151 to -1335 of the rat CYP7 gene. This sequence has been demonstrated to bind Sp1 which is a positive transcription factor in the LDL receptor gene (Dawson, et al. J. Biol. Chem. 263, 3372-3379, 1988).

1 (B) The Human Gene

A human genomic library, which had been constructed with Sau3A1 partially digested human placental DNA ligated into a BamHI site of the EMBL-3 Sp6/T7 phage vector (Clontech, Palo Alto, Calif.) was screened using a 1.6 kb EcoRI-PstI fragment of a human cholesterol 7.alpha.-hydroxylase cDNA isolated previously as a hybridization probe. Human CYP7 cDNA was isolated previously by Karam and Chiang, BBRC 185:588 (1992). Hybridizations were carried out at a high stringency condition of 68.degree. C., 1% SDS and 0.1.times.SSC. 800,000 pfu of phages were screened. After four cycles of screening, seven positive clones were plaque-purified. Three clones comprising the largest inserts (.lambda.HG.alpha.26, .lambda.HG.alpha.5 and .lambda.HG.alpha.52) were isolated and analyzed by restriction mapping. FIG. 2A shows the complete gene map of human CYP7. Clone .lambda.HG.alpha.26 (FIG. 2B) contains a 15 kb insert which spans about 8.0 kb of the 5'-upstream flanking sequence and exons I to III (FIGS. 9 and 10 SEQ ID NOS 32 and 33). Clone .lambda.HG.alpha.5 (FIG. 2C) contains sequences from intron IV, exons V and VI to an 8.0 kb 3'-flanking sequence (FIG. 11 SEQ ID NO: 34).

Cloned bacteriophage .lambda.HG7.alpha.26 and .lambda.HG7.alpha.5 were deposited Aug. 25, 1993 at the American Type Culture Collection, ATCC, 12301 Parkland Drive, Rockville, Md. 20852, U.S.A., under accession numbers ATCC 75534 and 75535, respectively.

Five EcoRI fragments of the clone .lambda.HG.alpha.26 were excised from the phage DNA insert by restriction digestion and shotgun subcloned into the phagemid vector pBluescript II KS+ (Stratagene, La Jolla, Calif.). The clones were size-selected. EcoRI fragments were isolated from CsCl purified plasmids and used for sequencing. Nested deletions were generated by ExoIII/Mung Bean nuclease digestion according to the manufacturer's instruction (Stratagene, Calif.) using the conditions of a 37.degree. C. incubation for 1 min intervals. This condition resulted in an average deletion of about 200 to 250 bp/min. DNA sequencing of the nested deletions was carried out by the dideoxy chain termination method using T7 sequence version 2.0 (USB, Cleveland, Ohio) and .sup.35 S-dATP. Sequence data were obtained from both strands and the overlapping deletion clones and analyzed using DNASIS software (Hitachi America, Calif.).

The nucleotide sequences of a 5.5 kb EcoRI fragment (FIG. 9 SEQ ID NO: 32) and a 2.6 kb EcoRI fragment (FIG. 10 SEQ ID NO: 33) were determined. The 5 kb fragment contains the sequence from -1886 of the 5'-upstream region to a partial exon 3 (FIG. 2B). Included in FIG. 9 (SEQ ID NO: 32) also is the 347 bp 3'-end sequence of a 3.5 Kb EcoRI fragment located immediately upstream of this 5.5 kb fragment (FIG. 2B). As shown in FIG. 2A, the 2.6 kb fragment is located further 5' upstream of the 3.5 kb EcoRI fragment. Thus, a 4823 bp 5'-upstream flanking region sequence of the gene now is determined.

Molowa et al. (Biochem. 31, 2539-2544, 1992) published a 1.7 kb upstream sequence of a human gene. A comparison of the sequence of the present invention to that of Molowa et al. in the overlapping region (1604 bp) revealed that sequences from the transcription start site to about -460 are identical, however, further upstream the sequence vary significantly. A total of 52 sequence discrepancies were found, which are far too many to attribute only to the presence of polymorphisms in the human gene. Cohen et al. (Genomics, 14, 153-161, 1992) reported a 723 bp upstream sequence and suggested sequencing errors by Molowa et al. Thus, the sequence of the present invention, from the transcription start site (nt+1) to -587, is identical to those reported previously by Molowa et al., Nishimoto et al., (Biochem. Biophys. Acta, 1122, 147-150, 1993) and Thompson et al., (Biochim. Biophys. Acta. 1168, 239-242, 1993).

The present invention identifies seven mismatches in Cohen's sequence from +1 to -123. A conversion of at T to C nucleotide -469 was identified to be a Mae II polymorphism (Thompson et al., 1993). The 5'-flanking sequence of the present invention agrees very well with that reported by Thompson et al. (1993). Only one mismatch at nucleotide -1193 (C vs A) was found in the overlapping region from +1 to nucleotide -2235.

The present invention further identifies transcription factor binding motifs in the human gene, however, SRE-like sequences were not found in the human promoter region. 1. (C) The Hamster Gene

A hamster liver genomic library constructed in the .lambda.DASH II vector (Stratagene) was screened with a 2.5 kb Eco RI fragment of the rat pBSK7.alpha.12 comprising the entire coding sequence of the rat cholesterol 7.alpha.-hydroxylase cDNA. About 1 million plaque-forming units were screened and one positive clone was identified and plaque-purified. The phage DNA was purified by CsCl gradient centrifugation and cDNA insert was restriction-mapped using rat probes (FIG. 3). EcoRI fragments of the DNA were isolated and subcloned into a pBluescript II KS+ vector. Nested deletions were generated with an ExoIII/Mung Bean deletion kit. The DNA sequences of these deletions were determined by the dideoxy chain termination method using Sequenase. In some instances 17-mer synthetic oligonucleotides were designed and used as sequencing primers. Sequences were determined on both strands with overlaps. cDNA sequence analyses were carried out with DNASIS software.

FIG. 12 (SEQ ID NO: 35) shows the 11 kb DNA sequence of the hamster gene. It covers the sequence from nucleotide- 1650 of the 5'-flanking region through all six exons and five introns (Exon I: nucleotide 1651-1730; Exon II: 3511-3650; Exon III: 4351-4937; Exon IV: 5945-6075; Exon V: 7690-7865; Exon VI: 8437-8736). The amino acid codons interrupted by introns are identical in each of these three homologous genes. The DNA sequence of the exon-intron junctions follows the canonical GT-AG rule typical of eukaryotic genes. The precise intron sizes determined by DNA sequencing are consistent with those of the rat. The intron 3 of the hamster gene is 1007 bp, which is about 1 kb shorter than that estimated for human intron 3. A putative polyadenylation signal (AATAAA) is located 371 bp upstream from the 3'-end of the gene, indicating that the isolated genomic clone should include the entire coding exon 6.

EXAMPLE 2

REGULATORY ELEMENTS AND TRANSCRIPTION FACTORS

Cloning of the CYP7 gene from three different species allows the analysis of the CYP7 gene structure and organization. Alignment and analysis of the highly conserved proximal promoter region of these homologous gene suggests that many regulatory elements are conserved and are likely to play important roles in gene regulation. Mapping of these transcription factor binding sites is essential to the isolation of transcription factors involving in the regulation of liver-specific CYP7 gene transcription. These sequence elements and protein factors are potential models for designing compounds and for screening for activators or repressors of the gene, such as described in a parent U.S. application Ser. No. 08/135,488, to Chiang, J. The following discussion relates to the regulatory elements and transcription factors of the rat gene promoter.

2.1. Alignment and Analysis of the CYP7 Genes

The proximal promoter regions of the rat, human and hamster genes were aligned. Sequence identity is about 82% between rat and hamster, 77% between hamster and human and 71% between human and rat (FIG. 4 SEQ ID NOS 25, 26 and 27 respectfully). Several liver-enriched transcription factors, HNF3, HNF4, HNF1 and C/EBP, and thyroid/steroid hormone response elements are highly conserved in these homologous genes (FIG. 5). Sequences that are further upstream of these genes have diverged considerably. In contrast to the report that the -400 proximal promoter of the human gene had no promoter activity (Molowa, et al. Biochem. 31, 2539-2544, 1992), this conservation indicates that the proximal promoter is important in transcriptional activation function and contains essential regulatory elements.

2.2. Footprint Analysis of the Rat Gene

DNase I hypersensitivity sites of the rat gene were mapped by digestion of rat liver nuclei (20 OD.sub.260) with DNase I at 37.degree. C. for time periods up to 4 minutes. DNA was isolated from nuclei at each time interval and digested with SacI, fractionated on a 0.8% agarose gel and transferred to nylon membranes. A 5'-probe of Sac I-EcoRI fragment (-3643 to -2265) was used for indirect end-labeling and was labeled with an activity of at least 1.times.10.sup.9 CPM/.mu.g. Four DNase I hypersensitivity sites (HSI, HSII, HSIII, HSIV) were mapped. HSI is mapped near a "CA" repeat region around nucleotide-1,500. HSII is located in the proximal promoter region. HSIII and HSIV are located in intron I and intron II, respectively (FIG. 6).

DNase I footprinting technique then was applied to map the transcription factor binding sites in the gene promoter (Heberlein,U, England, B and Tjian, R Cell, 41, 965-977, 1985). Transcription factor binding sites in the gene are protected from DNase I digestion. Two fragments were mapped: a Hind III-Xba I fragment (-346 to +36) in the proximal promoter region near the hypersensitivity site II and an upstream fragment Xba I-Hind III(-1530 to -1205) in the hypersensitivity site I. Probes were made from plasmid DNA digested with a restriction enzyme to generate a 5'-overhang, filled in with the Klenow fragment of DNA polymerase I and .sup.32 P-labeled dCTP, and then digested with a second restriction enzyme. Probes were purified from a native 5% polyacrylamide gel. Footprinting reactions included 2 .mu.g of poly(dI-dC), 10% polyvinyl alcohol, 50 mM KCl and 20 fmol of probe in a volume of 50 .mu.l. Reactions were stopped with EDTA and SDS, then phenol extracted, ethanol precipitated and run on polyacrylamide sequencing gels.

The footprinted areas are summarized as follows:

Footprints (FP) mapped in hypersensitivity site II: FP I (Nucleotides -81 to -37): TGT3, 7.alpha.-TRE, HNF1/LFB1, CAAT, Box elements 5'-TGTTTGCTTTGGTCACTCAAGTTCAAGTTATTGGATCATGGTCC-3' (SEQ ID NO: 3) FP II (Nucleotides -149 to -131): HNF4/LFA1 element 5'-CTATGGACTTAGTTCAAGG-3' (SEQ ID NO: 4) FP III (Nucleotides -171 to -154): GRE half site 5'-TGTTCTGGAGCCTCTTCT-3' (SEQ ID NO: 5) Footprint mapped in hypersensitivity site I: FP IV (Nucleotides -1448 to -1410): NF1 elements 5'-TCACTGTGGCCTAGTGCCACATCTACCTATTTCTTTGGCTTTAC- 'TTTGT-3' (SEQ ID NO: 6)

Footprint I covers a sequence from nucleotide -81 to -37 and consists of four elements: TGT3/HNF3, 7.alpha.-TRE, LFB1/HNF1, and CAAT box (reversed). Footprint II covers sequence from -149 to -131 and contains an LFA1/HNF4 site. Footprint III covers sequences from -171 to -154 and contains a consensus glucocorticoid response element (GRE) half site. In the hypersensitivity site I, a footprint covers -1554 to -1505 and contains a bipartite and a half-site of the NF1/CTF element. Most of these sequences are liver-enriched transcription factor consensus motifs and are highly conserved in all three species. It is especially interesting that Footprint I contains overlapping binding sites for at least four transcription factors, HNF3.alpha./3.beta., 7.alpha.-TRE, HNF1/LFB1, and C/EBP. The TRE-like sequence (SEQ ID NO: 7) (TGGTCANNNNAGTTCA) located in the center of the cluster may be the binding site for Type II hormone receptors such as the T.sub.3 receptor (T.sub.3 R), the retinoic acid receptor (RAR), the retinoid X receptor (RXR), the vitamin D.sub.3 receptor (VD.sub.3 R), or the peroxisome proliferator activating receptor (PPAR) (Stunnenberg, HG, BioEssays, 15, 309-315, 1993). This gene fragment has been shown to be essential for major promoter activity and could confer taurocholate repression of promoter activity in rat primary hepatocyte cultures. It is likely that the element in footprint I identified in the present invention is a bile acid response element (BARE) of the CYP7 gene.

2.3. Gel Mobility Shift Analysis of the Rat Gene

The electrophoretic mobility shift assay (EMSA) is used to detect specific DNA-protein interactions in the identified footprints. Oligonucleotides corresponding to PPRE/TRE, 7.alpha.TRE, and TGT3 were synthesized and annealed to form double-stranded probes. DNA fragments corresponding to Footprints I, II, and IV were generated by PCR using primers that flank the footprint sequences. Probes are labeled with .sup.32 P dCTP by the Klenow fragment of DNA polymerase I. Probes were gel purified before use. Binding reactions were done in 20 .mu.l comprising 10% glycerol, 10 mM HEPES, pH 7.9, 2 .mu.g of poly(dI-dC), 1 .mu.g of nuclear protein extracts and 20,000 CPM of probes at 30.degree. C. for 15 min, followed by electrophoresis on 4% native polyacrylamide gels (Carthew, R. W., et al. Cell, 43, 439-448, 1985).

The footprint I probe shifted at least 4 bands when it was reacted with liver nuclear extract. Cold competitor specifically prevented band shifts. The footprint II probe shifted two bands whereas Footprint IV probe shifted only one band with liver nuclear extract. Since Footprint I contains several transcription factor binding elements and is the possible bile acid receptor or binding protein (BAR) binding site, double-stranded oligonucleotides were synthesized corresponding to the TGT3 and 7.alpha.-TRE elements in Footprint I.

EMSA revealed that the TGT3 element shifted two major bands, which may be due to the binding of HNF3.alpha. and HHF3.beta., whereas the 7.alpha.-TRE element shifted two different bands. Protein factors that bind to the 7.alpha.-TRE probe could be competed out with a 100-fold excess of its cold competitor or a rat growth hormone gene TRE element. However, TGT3 and PPAR/TRE oligonucleotides did not compete with the 7.alpha.-TRE probe. These results indicate that the 7.alpha.-TRE like element identified in the CYP7 gene promoter binds to one or two specific liver protein factors. In addition, the 7.alpha.-TRE of the human CYP7 gene (FIG. 4) also shifted one band in human liver nuclear extracts.

Furthermore, EMSA was performed using liver nuclear extracts isolated from rats treated with a diet supplemented with 0.25% deoxycholate, 1% cholate, 5% cholestyramine or 1% cholesterol for two weeks. Only nuclear extracts from deoxycholate-treated rat liver abolished the gel shift of the 7.alpha.-TRE oligonucleotide. Deoxycholate or sodium cholate treatment reduced both cholesterol 7.alpha.-hydroxylase activity and mRNA levels by 80% and 60%, respectively, whereas cholestyramine or cholesterol treatment stimulated these parameters by 330% and 180%, respectively.

These results suggested that deoxycholate may inhibit the binding or synthesis of a positive nuclear transcription factor, (i.e. factor A) to a bile acid responsive element (BARE) or inhibit the synthesis of factor A in nuclei as well as repress CYP7 gene expression. Alternatively, deoxycholate may bind to a negative regulator, BAR, which forms a complex with the positive factor A and prevents the binding of factor A with BARE. BAR and nuclear transcription factor A may compete for the same binding site, BARE. These factors are likely members of the steroid/thyroid hormone supergene family, since the recognition sequence is similar to the cognate response element. Interactions between this transcription BAR with adjacent liver-enriched transcription factors (HNF3.alpha., HNF3.beta., HNF1, C/EBP) can affect the expression levels of the CYP7 gene.

2.3 (a) Effect of Bile Acids on EMSA: Further Results

A gel shift experiment was performed to further confirm that the 7.alpha.TRE and the DR.sub.0 elements are bile acid responsive elements. Liver nuclear extracts isolated from rats treated with dietary supplements specified above were used. Deoxycholic acid and sodium cholate treatment significantly suppressed both cholesterol 7.alpha.-hydroxylase activity and mRNA levels by about 80% and 60%, respectively. On the other hand, 5% cholestyramine or 1% cholesterol stimulated activity and mRNA level by 330% and 180 respectively.

The rat 7.alpha.TRE element shifted one band in human nuclear extracts, while the human 7.alpha.TRE shifted one band in all rat nuclear extracts that were treated with cholestyramine, sodium cholate and cholesterol. In deoxycholate-treated rat liver nuclear extracts, however, human 7.alpha.TRE did not shift any protein band. All other nuclear extracts showed similar band patterns (no shift) as that of the control (non-treated rat) extracts. From the gel generated by this experiment, it was observed that 7.alpha.TRE shifted two bands whereas rat DR.sub.0 shifted one. Thus, rat DR.sub.0 element appeared to bind the transcription factor more specifically than did 7.alpha.TRE. Accordingly, the rat DR.sub.0 element was selected for use as a probe to demonstrate the presence of transcription factor on a Southwestern blot, discussed below.

2.3 (b) Characterization of a DNA-Binding Protein

A Southwestern blot, which illuminates DNA-protein interactions, was performed to reveal nuclear protein factor(s) that bind to the rat DR.sub.0 element, which appears to bind a transcription factor more specifically than 7.alpha.-TRE. This rat probe predominantly bound to a polypeptide of about 57,000 .+-.7000 Daltons which showed a similar band width in all rat liver nuclear extracts tested, including extracts from non-treated rats and rats treated with cholestyramine, sodium cholate, cholesterol and deoxycholate.

The rat DR.sub.0 revealed a second band shift of 116,000 daltons in all of these extracts as well. This second shift is believed to constitute a dimer of two 57 KDa peptides. The 57 KDa polypeptide was also present in nuclear extracts of rat spleen, rat kidney and human liver, although the band was less pronounced in the human liver extracts.

Methods of substantially isolating transcription factors according to the invention, for example, can employ DNA fragments according to the invention in conjunction with methodology taught by Singh et al., Cell 52:415 (1988) and Kadonaga et al., PNAS USA 83:5889 (1986). Each of these publications is incorporated by reference herein in their entirety. Yet another approach to identify and clone genes for proteins that interact with DNA-binding protein employs yeast two-hybrid system to study protein-protein interaction (Fields and Song, 1989; Chien et al. PNAS 88:1958 (1991)). The Chien publication is incorporated by reference herein in its entirety.

2.4 Recognition site affinity chromatography

One approach to isolating a transcription factor provides the advantage of isolating a protein complex that includes both a DNA-binding protein and other associated protein factors that interact with the a DNA-binding protein. The success of purification of transcription factor is dependent, generally, on parameters including the quality of nuclear extracts, the amount of transcription factors present in the extracts, and the binding affinity of the DNA-affinity column. Also, the binding site sequence selected for use in the column is optimized by EMSA, DNase I footprinting, mutational analysis and by sequence comparison of homologous binding site.

A BARE consensus sequence, such as that identified by the present invention can be utilized advantageously in an affinity column. The rat or human 7.alpha.TRE or DR.sub.0, which recognized a single binding protein in EMSA of either human or rat nuclear extracts, is suitable for DNA affinity column chromatography and identifies a 57 KDa bile acid responsive protein.

Affinity chromatography is performed according to the following protocol. First, cell-free nuclear extracts are obtained from either HepG2 cells or human liver tissues. Fresh human liver tissue is advantageous for isolating nuclear extracts, however, it sometimes difficult to obtain. Nuclear proteins are extracted with high salt and crude extracts are precipitated with ammonium sulfate, dialyzed and then subjected to gel filtration column (i.e., Sephacryl S-300, Pharmacia) or a heparin-agarose affinity column (Sigma Chemical). Column fractions are assayed for transcription factors by EMSA and pooled fractions are applied to a sequence-specific affinity column.

A DNA affinity column is prepared which employs double-stranded BARE consensus oligonucleotides according to the invention, which are provided with a 5' overhang of nucleotides "gatc". The oligonucleotides are concatemerized by phosphorylation with T4 polynucleotide kinase and ligated by T4 DNA ligase (Jackson et al., GENE TRANSCRIPTION: A PRACTICAL APPROACH, ed. Hames and Higgins, I.R.L. Press 189-242 (1993). The disclosure of the relevant section of this book concerning affinity chromatography methodology is expressly incorporated herein by reference in its entirety. The ligated, concatemerized DNA is covalently attached to a CNBr-activated Sepharose Cl2B gel (Pharmacia) (Kadonaga, 1986 supra)

A transcription factor preparation isolated by the column is subjected to SDS-polyacrylamide gel electrophoresis. Thereafter, the gel is stained with silver staining to demonstrate the preparation's purity, and the DNA-binding properties of the purified transcription factor measured using EMSA and DNase I footprinting.

Once a transcription factor is purified, it can be used to raise antibodies, which in turn are used as a screening probe to isolate cDNA clone encoding the transcription factor. For example, the purified 57 KDa BARP is used to raise antibodies against itself, which are used as a screening probe to isolate its cDNA. 2.4 (a) Screening using recognition-site sequences

An alternate method of isolating a BARP includes directly cloning cDNAs encoding a BARP from human liver cDNA expression libraries (Promega, Clontech), which are screened for a fusion protein recognizing specific nucleotide sequences. This technique is perhaps simpler than affinity chromatography, but it yields cDNA(s) that encode a DNA-binding protein, not protein itself.

Binding site probes of a BARE consensus sequence according to the invention are prepared by 5'-end labelling a double-stranded oligonucleotide with .gamma.-.sup.32 P ATP using T.sub.4 polynucleotide kinase. T4 DNA ligase is then used to concatamerize oligonucleotides. Human liver .lambda.gt11 cDNA expression libraries will be screened following routine procedure described by Sambrook et al., Mol. Cell Biol. 9:946 (1989).

Fusion proteins are induced by overlaying the plates with IPTG-treated nitrocellulose filters and incubating for 6 hours at 37.degree. C. Filters are soaked in 6M guanidinium chloride in binding buffer and washed in the same buffer but gradually reducing the concentration of denaturant to 0.188M, and finally in buffer without denaturant. Filters are placed in binding buffer, and blocked in non-fat mild solution and incubate with binding site probe at 4.degree. C. overnight. Filters are washed and autoradiographed at -70.degree. C.

Positive plaques are picked, replated and screened until plaque-purified. cDNA is sequenced by dideoxy chain termination method using Sequenase Kit (USB Co.) and analyzed with DNA analysis software. Amino acid coding sequences are analyzed for sequence motifs and compared against GenBank database for characteristics of DNA-binding proteins, such as possessed by a zinc finger, leucine zipper or member of a nuclear receptor gene family. 2.5 Characterizing transcription factors

To overexpress a BARP for footprinting and transient transection assays, its cDNA is isolated according to the protocol of 2.3 (b) and subcloned into a pMT eukaryotic expression vector (Kaufman et al., 1989). For gel shift assay, cDNA will be subcloned into pGEM4 (Promega). Plasmid is linearized and in vitro transcribed by SP6 RNA polymerase. The resulting RNA is translated in a rabbit reticulocytes lysate system in the presence of .sup.35 S-methionine.

EMSA is performed as described herein. In vitro synthesized protein is incubated with .sup.32 P-labeled probe and electrophoresed in low ionic strength polyacrylamide gel. Two filters are placed against the dried gel, the first of which blocks the .sup.35 S radiation.

CYP7 promoter/luciferase constructs and pMT plasmid carrying a BARP cDNA are transiently cotransfected into HepG2 cells by calcium phosphate coprecipitation method as described previously. pRSV-.beta.gal plasmid is used as an internal standard for normalization of transection efficiency. A test agent or endogenous factor is added in culture media and incubated for a period of time. Cells are lysed, then luciferase activity is measured, as described previously.

__________________________________________________________________________Electrophoretic Mobility Shift Assay of DNA-protein InteractionsSequences of double-stranded probes # of bands__________________________________________________________________________ shifted1). FP I probe (-100 to -29): (SEQ ID NO:8) four to five5'-CTAGTAGGAGGACAAATAGTGTTTGCTTTGGTCACTCAAGTTCAAGTTATTGGATCATGGTCC-3'GATCATCCTCCTGTTTATCACAAACGAAACCAGTGAGTTCAAGTTCAATAACCTAGTACCAGG-5'3'-2) FP II probe (-161 to -127): (SEQ ID NO:9) two5'-CCTCTTCTGAGACTATGGACTTAGTTCAAGGCCGG-3'3'-GGAGAAGACTCTGATACCTGAATCAAGTTCCGGCC-5'3). FP IV probe (-1454/-1394): (SEQ ID NO:10) one5'-TCACTGTGGCCTAGTGCCACATCTACCTATTTCTTTGGCTTTACTTTGTGCTAGGTGACC-3'3'-AGTGACACCGGATCACGGTGTAGATGGATAAAGAAACCGAAATGAAACACGATCCACTGG-5'4). PPRE/TRE element probe (nt -101/-82): two5'-GAAGATCTAGTAGGAGGACAAATAG 3' (SEQ ID NO:11)3' CATCCTCCTGTTTATCAC 5' (SEQ ID NO:12)5). 7.alpha.-TRE element probe (nt -73/-56 in FP I): two5'-GATCCTTGGTCACTCAAGTTC 3' (SEQ ID NO:13)3' GAACCAGTGAGTTCAAGTTCCTAG 5' (SEQ ID NO:14)6). TGT3 element probe (nt -86/-71 in FP I): two5'-GATCCAATAGTGTTTGCTTTGGT 3' (SEQ ID NO:15)3' TCACAAACGAAACCATCCTAG 5' (SEQ ID NO:16)__________________________________________________________________________ 2.6 Promoter/Reporter Gene Constructs

To determine the promoter sequences responsible for regulation of cholesterol 7.alpha.-hydroxylase, deletions of the rat CYP7 promoter were ligated upstream of the luciferase reporter gene (Luc). The promoter fragments were generated by the polymerase chain reaction using the primers listed with a rat CYP7 genomic clone as the template. The fragments were blunted by filling in with the Klenow fragment of DNA polymerase and then digested with Xho I. The fragments were then ligated into the pGL2-basic vector (Promega) which had been digested with SmaI and Xho I, and transformed into E. coli HB101 cells. The resulting plasmids (pLUC-224, pLUC-160, pLUC-101, and pLUC-3600) are used to transfect primary hepatocytes or hepatoma cells for the study of luciferase gene expression under the control of the CYP7 promoter. The results show that pLUC-224 had two-fold higher luciferase activity than pLUC-160 and pLUC-3600 when transfected into rat primary hepatocytes. pLUC-3600 had transcription activity similar to that of pLUC-160. In addition, 50.mu.M taurocholate inhibited the expression of luciferase activity in these hepatocytes, indicating that these CYP7 gene promoter fragments do contain a BARE, which confers bile acid regulation.

To determine if the sequence from -101 to -29 of the CYP7 gene promoter can function as an enhancer element, the region was cloned into the pGL2-Promoter vector (Promega). The vector is similar to pGL2-basic, with the addition of the SV40 early promoter between the multiple cloning site and the luc gene. The rat sequence was amplified by the polymerase chain reaction to flank the sequence with a BamHI site and a BglII. The fragment was ligated in both orientations to the pGL2-Promoter, which had been cleaved with BglII. The resulting plasmids are named pLUC-101/-29 and pLUC-29/-101.

Chloramphenicol acetyltransferase (CAT) reporter gene constructs were made by using the polymerase chain reaction and primers to amplify the region -415 to +36 of the rat CYP7 gene and to incorporate an XbaI at nucleotide +36. The blunt ended, Xba I digested fragment was ligated into a promoter-less pCAT basic vector (Promega) which had been digested with Sal I, blunt-ended and digested with Xba I to yield -415CAT. A longer construct named -3643CAT was made by digesting -415CAT with Hind III and inserting a 3.2 kb Sac I-Hind III genomic fragment. The 3.6 kb insert was removed from -3643CAT and ligated into a pGL2-basic vector (Promega). This plasmid was used to generate nested deletions with Exo III and S1 nuclease.

__________________________________________________________________________Promoter/Reporter Gene ConstructsPCR primers used for PCR of fragments +30L1: 5'-AGATGGCTCGAGACTCTTTGCCTAGCAAA-3' (SEQ ID NO:17) XhoI-224L3: 5'-CAGCACATGAGGGACAG03' (SEQ ID NO:18)-160L4: 5'-CTCTTCTGAGACTATGGAC-3' (SEQ ID NO:19)-101L8: 5'-GAAGATCTAGTAGGAGGACAAATAG-3' (SEQ ID NO:20BglIISequence of promoter fragments inserted in pGL2-basic vectorpLUC-224: 5'-CAGCACATGAGGGACAGACCTTCAGCTTATCGAGTATTGCAGCTCTCTGTTT GTTCTGGAGCCTCTTCTGAGACTATGGACTTAGTTCAAGGCCGGGTAATGCTATT TTTTTCTTCTTTTTTCTAGTAGGAGGAGGACAAATAGTGTTTGCTTTGGT CACTCAAGTTCAAGTTATTGGATCATGGTCCTGTGCACATATAAAGTCTAGTCAGA CCCACTGTTTCGGGACAGCCTTGCTTTGCTAGGCAGGCAAAGAGTCTCGAG-3' (SEQ ID NO:21) XhoIpLUC-160: 5'-CTCTTCTGAGACTATGGACTTAGTTCAAGGCCGGGTAATGCTATTTTTTTCT TCTTTTTTCTAGTAGGAGGACAAATAGTGTTTGCTTTGGTCACTCAAGTTCA AGTTATTGGATCATGGTCCTGTGCACATATAAAGTCTAGTCAGACCCACT GTTTCGGGACAGCCTTGCTTTGCTAGGCAGGCAAAGAGTCTCGAG-3' (SEQ ID NO:22) XhoIpLUC-101 5'-GAAGATCTAGTAGGAGGACAAATAGTGTTTGCTTTGGTCACTCAAGTTCA AGTTATTGGATCATGGTCCTGTGCACATATAAAGTCTAGTCAGACCCACT GTTTCGGGACAGCCTTGCTTTGCTAGGCAGGCAAAGAGTCTCGAG-3' (SEQ ID NO:23) XhoIpLUC-3600: 3.6 kb 5' flanking sequence to +36Sequences of promoter fragments inserted in pGL2-promoter vector:pLuc-1010/-29: -101 GAAGATCTAGTAGGAGGACAAATAGTGTTTGATTTGGTCACTCAAGTTC -29 AAGTTATTGGATCATGGTCCTGTGCACATCCTAGGGC-3' (SEQ ID NO:24)pLuc-29/-101: Reversed direction of the above sequencePromoter/CAT gene constructs:-415CAT: sequence from -415 to +36-3643CAT: 3.6 kb 5'-upstream sequence to +36__________________________________________________________________________

EXAMPLE 3

HepG2 CELLS TRANSFECTED WITH PROMOTER/REPORTER GENE CONSTRUCTS

3.1 HepG2 cell cultures

HepG2 cells were obtained from ATCC (Bethesda, Md.) and grown in Dulbecco's Modified Eagles Medium/F12 (50:50) supplemented with 10% heat inactivated fetal bovine serum, 1 mM Minimum Essential Medium (MEM) sodium pyruvate, 1.times.MEM non-essential amino acids, 25 mM Hepes, 100 U/ml penicillin G and 100 mg/ml streptomycin in a humidified incubator with 5% CO.sub.2 in air at 37.degree. C. Forty-eight hours prior to the isolation of RNA, the media were replaced with fresh media containing bile salts but without fetal calf serum. The monolayers were grown to either subconfluent (50 to 70% confluent) or confluent. Viability of the cells was checked by Trypan Blue exclusion test. About 40 million cells were lysed by the addition of 4M guanidinium thiocyanate, 0.5% N-lauroylsarcosine, 25 mM sodium citrate, pH 7.0, and 0.1M 2-mercaptoethanol, phenol extracted, and ethanol precipitated. Poly (A+) RNA was isolated using PolyAT tract mRNA isolation system III according to the manufacturer's instructions (Promega, Madison, Wis.). A PstI fragment of human cholesterol 7.alpha.-hydroxylase cDNA was labeled with .sup.32 P and used as a hybridization probe, according to the method of Karam et al., Biochem. Biophys. Res. Commun. 185:588 (1992). Human actin cDNA was used to hybridize the same membrane and served as an internal standard for the normalization of RNA level which were quantitated by scanning each lane with a laser scanner.

For transient transfection assay, cells were split and plated for at a density of 10.sup.6 cells/60 mm Petri dish and grown to subconfluence (about 30% confluence) or to confluence.

3.2 Clarifications concerning the rat CYP7 promoter/reporter gene constructs utilized

Constructs pLUC-3600, pLUC-224, and pLUC-160 were constructed according to the description in section 2.4 above, with the following minor corrections to their nomenclature noted for the sake of exactness. First, as shown in the sequences listed above, the promoter sequences of all three constructs share the common endpoint, nucleotide +32 of the CYP7 DNA sequence, as opposed to nucleotide +36. The latter 4 nucleotides upstream of +32 include non-CYP7 bases that are a part of the exogenously-added Xho splice site. Second, as stated above, construct pLUC-3600 comprises a fragment encompassing the entire 3643 kilobase promoter region up until +32 of CYP7 gene. Accordingly this construct known figuratively as pLUC-3600 denotes a construct that contains a fragment between -3643 and +32 of CYP7.

Accordingly, three chimeric gene constructs, pLUC-3600, pLUC-224, and pLUC-160, represent deletion mutants generated by PCR using primers or by restriction digestion as described herein above. These three constructs were used for transient transfection assays in HepG2 cells.

3.3 Characterization of cholesterol 7.alpha.-hydroxylase mRNA in HepG2 cells

HepG2 liver cells express cholesterol 7.alpha.-hydroxylase normally, which makes these cells good candidates for the study of CYP7 regulation. To assess the suitability of these cell lines suitable for use in a transfection assay of the CYP7/reporter chimeric gene constructs, it was necessary to prove first that cholesterol 7.alpha.-hydroxylase activity could be regulated in these cells.

To characterize HepG2 cells, expression of cholesterol 7.alpha.-hydroxylase mRNA was measured in HepG2 control cells and cells treated with bile acids. Northern blot hybridization of poly (A+) RNAs isolated from confluent cultures of HepG2 cells, that were treated with media containing 100 .mu.M of tauro- (T) or glyco- (G) conjugate of cholate (CA), deoxycholate (DCA), chenodeoxycholate (CDCA) or ursodeoxycholate (UDCA) and incubated. Cholesterol 7.alpha.-hydroxylase cDNA hybridized to two mRNA species of 3 kb and 1.8 kb, in agreement with Hassan et al., Biochem. Pharmacal. 44:1475 (1992). Both of these RNA species apparently are 7.alpha.-hydroxylase mRNA because the two bands changed responsively in parallel.

In subconfluent cultures, only TCDCA could repress mRNA level. In contrast, tauroursodeoxycholate (TUDCA) significantly increased mRNA level in subconfluent HepG2 cells. Glyco-conjugates of bile acids had similar effects as the tauro-conjugates. At this concentration, bile acid did not reduce viability of HepG2 cells.

FIG. 13 summarizes the effects of bile acid conjugates on 7.alpha.-hydroxylase mRNA level in HepG2 cells. When 100 .mu.M taurocholate (TCA) was added, mRNA level was not changed significantly, while TDCA and TCDCA reduced mRNA level by 50 to 80% in confluent cultures. mRNA levels are expressed as % of mRNA level in cells without treatment of bile acids. Values are averages of three experiments. Thus, cholesterol 7.alpha.-hydroxylase mRNA level in HepG2 cells is regulated by bile acids. The inhibitory effect of bile acids follows the hydrophobicity indexes of bile acids, TCA<TDCA<TCDCA, as described by Heuman et al., Lipid Res. 30:1160 (1989). The results are also consistent with those observed in primary cultures of rat hepatocytes, as described by Hylemon et al., J. Biol. Chem. 267:16866 (1992).

3.4 Transient Transfection of HepG2 cells with rat CYP7 promoter/reporter constructs

CYP7 promoter/reporter constructs were transiently transfected into HepG2 cells using the calcium phosphate-DNA coprecipitation method, with 0.5 ml of coprecipitate containing 5 .mu.g of test plasmid (pLUC-3600, pLUC-224, and pLUC-160) and 1 .mu.g of .beta.-galactosidase expression plasmid, pCMV.beta. (Clontech), as an internal standard for transfection efficiency. After 4 hours, cells were shocked with 15% glycerol in TBS for 90 seconds, washed three times with TBS and further incubated for 42 hours in serum free medium containing 200 .mu.M tauro-conjugates of bile acids. Cells were washed twice with phosphate-buffered saline, lysed and harvested with 400 .mu.l of reporter lysis buffer (Promega) according to manufacturer's instruction.

Luciferase activity was assayed by mixing 20 .mu.l of cell extracts to 100 .mu.l of luciferase assay reagent (Promega) at room temperature and measuring light emission during the initial 10 seconds of the reaction. A luminometer (Lumat LB9501, Berthold) was used for this purpose. Luciferase activity was corrected for transfection efficiency.

3.5 Results: Transcriptional activity of CYP7 promoter/reporter constructs in HepG2 cultures

The promoter/reporter chimeric gene constructs according to the invention were transiently transfected into HepG2 cells to demonstrate the effect of bile acids on transcriptional activity. The untreated cells shown in FIG. 14 reveal that promoter activity of pLUC-224 was much higher than pLUC-3600, and pLUC-160. Enhancer activity therefore is believed to be located between nucleotides -224 and -160. In addition, a repressor is believed to be located upstream of nucleotide -224, between nucleotides -224 and -3643.

The hormone response elements are likely located upstream of nucleotide -224, according to the following experiment. Addition of 1 .mu.M thyroid hormone, T.sub.4 and 0.1 .mu.M dexamethasone increased transcriptional activity of pLUC-3600 by 2.5-fold in confluent cultures. However, this same amount of thyroid hormone and dexamethasone decreased the activity of pLUC-160 by 40% in subconfluent cultures, and had little effect on pLUC-224. Luciferase activity in each transfection experiment was expressed as % of activity in cells transfected with pGL2-control plasmid.

That bile acid response elements are located in the proximal promoter region, nucleotides -160 to +32, and also in region upstream of nucleotide -224 was revealed by the following experiment. Addition of 200 .mu.M TCA, TDCA or TCDCA did not affect transcriptional activity of the promoter/reporter constructs transfected into subconfluent HepG2 cultures, as shown in FIG. 15B. Luciferase activity in transfected cells was expressed as % of activity in transfected cells without treatment with bile acids. However, in the confluent cells, TDCA and TCDCA repressed transcriptional activity of p-pLUC-3600 by more than 70% and repressed activity of pLUC-224, or pLUC-160 by up to 45% (FIG. 15A). TCA, however, did not affect transcriptional activities of these gene constructs in HepG2 cultures.

It will be apparent to those skilled in the art that various modifications and variations can be made to the compositions of matter and processes of this invention. In particular, various kinds of screening assays are encompassed that employ human CYP7 regulatory elements or its analogs. Thus, it is intended that the present invention cover the modifications and variations provided they fall within the scope of the appended claims and their equivalents.

All references to publications set forth above are expressly incorporated by reference in their entirety herein.

__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 37(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:ATCCTCTCCCCACTCCCAAGCATCCCTCCATG32(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 16 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:CAACTCCTCCCCTATT16(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 44 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:TGTTTGCTTTGGTCACTCAAGTTCAAGTTATTGGATCATGGTCC44(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:CTATGGACTTAGTTCAAGG19(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:TGTTCTGGAGCCTCTTCT18(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 49 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:TCACTGTGGCCTAGTGCCACATCTACCTATTTCTTTGGCTTTACTTTGT49(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 16 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:TGGTCANNNNAGTTCA16(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 63 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:CTAGTAGGAGGACAAATAGTGTTTGCTTTGGTCACTCAAGTTCAAGTTATTGGATCATGG60TCC63(2) INFORMATION FOR SEQ ID NO:9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:CCTCTTCTGAGACTATGGACTTAGTTCAAGGCCGG35(2) INFORMATION FOR SEQ ID NO:10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 60 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:TCACTGTGGCCTAGTGCCACATCTACCTATTTCTTTGGCTTTACTTTGTGCTAGGTGACC60(2) INFORMATION FOR SEQ ID NO:11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:GAAGATCTAGTAGGAGGACAAATAG25(2) INFORMATION FOR SEQ ID NO:12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iv) ANTI-SENSE: YES(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:CACTATTTGTCCTCCTAC18(2) INFORMATION FOR SEQ ID NO:13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:GATCCTTGGTCACTCAAGTTC21(2) INFORMATION FOR SEQ ID NO:14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iv) ANTI-SENSE: YES(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:GATCCTTGAACTTGAGTGACCAAG24(2) INFORMATION FOR SEQ ID NO:15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:GATCCAATAGTGTTTGCTTTGGT23(2) INFORMATION FOR SEQ ID NO:16:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(iv) ANTI-SENSE: YES(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:GATCCTACCAAAGCAAACACT21(2) INFORMATION FOR SEQ ID NO:17:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 29 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:AGATGGCTCGAGACTCTTTGCCTAGCAAA29(2) INFORMATION FOR SEQ ID NO:18:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:CAGCACATGAGGGACAG17(2) INFORMATION FOR SEQ ID NO:19:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:CTCTTCTGAGACTATGGAC19(2) INFORMATION FOR SEQ ID NO:20:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:GAAGATCTAGTAGGAGGACAAATAG25(2) INFORMATION FOR SEQ ID NO:21:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 264 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:CAGCACATGAGGGACAGACCTTCAGCTTATCGAGTATTGCAGCTCTCTGTTTGTTCTGGA60GCCTCTTCTGAGACTATGGACTTAGTTCAAGGCCGGGTAATGCTATTTTTTTCTTCTTTT120TTCTAGTAGGAGGAGGACAAATAGTGTTTGCTTTGGTCACTCAAGTTCAAGTTATTGGAT180CATGGTCCTGTGCACATATAAAGTCTAGTCAGACCCACTGTTTCGGGACAGCCTTGCTTT240GCTAGGCAGGCAAAGAGTCTCGAG264(2) INFORMATION FOR SEQ ID NO:22:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 199 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:CTCTTCTGAGACTATGGACTTAGTTCAAGGCCGGGTAATGCTATTTTTTTCTTCTTTTTT60CTAGTAGGAGGACAAATAGTGTTTGCTTTGGTCACTCAAGTTCAAGTTATTGGATCATGG120TCCTGTGCACATATAAAGTCTAGTCAGACCCACTGTTTCGGGACAGCCTTGCTTTGCTAG180GCAGGCAAAGAGTCTCGAG199(2) INFORMATION FOR SEQ ID NO:23:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 145 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:GAAGATCTAGTAGGAGGACAAATAGTGTTTGCTTTGGTCACTCAAGTTCAAGTTATTGGA60TCATGGTCCTGTGCACATATAAAGTCTAGTCAGACCCACTGTTTCGGGACAGCCTTGCTT120TGCTAGGCAGGCAAAGAGTCTCGAG145(2) INFORMATION FOR SEQ ID NO:24:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 86 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:GAAGATCTAGTAGGAGGACAAATAGTGTTTGATTTGGTCACTCAAGTTCAAGTTATTGGA60TCATGGTCCTGTGCACATCCTAGGGC86(2) INFORMATION FOR SEQ ID NO:25:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 255 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:GAGTATTGCAGCTCTCTGTTTGTTCTGGAGCCTCTTCTGAGACTATGGACTTAGTTCAAG60GCCGGGTAATGCTATTTTTTTCTTCTTTTTTCTAGTAGGAGGACAAATAGTGTTTGCTTT120GGTCACTCAAGTTCAAGTTATTGGATCATGGTCCTGTGCACATATAAAGTCTAGTCAGAC180CCACTGTTTCGGGACAGCCTTGCTTTGCTAGGCAAAGAGTCTCCCCTTTGGAAATTTTCC240TGCTTTTGCAAAATG255(2) INFORMATION FOR SEQ ID NO:26:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 255 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:TATCAAGTATTGAAGCTCTCTGCTTGTTTTGGAGCCTCTTCTGATACTATGGACTTAGTT60CAAGGCTGGGCAATACTATTTTTTTCTTTTTTCTAATAGGAGGACAAATAGTTAGTTGTT120TGCTTTGGTCATCCAAGTTCAAGTTATTGGATCATGGTCCTATGTGTATAAAGAGTCTAG180TTTGAGCCTTTCAGGGGCAGCCTTGCTGGCTAAGCACAGACTCTCCTCTTGGGAGTTTTC240CTGCTTTGCAAAATG255(2) INFORMATION FOR SEQ ID NO:27:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 254 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:GTATTGCAGGTCTCTGATTGCTTTGGAACCACTTCTGATACCTGTGGACTTAGTTCAAGG60CCAGTTACTACCACTTTTTTTTTTCTAATAGAATGAACAAATGGCTAATTGTTTGCTTTG120TCAACCAAGCTCAAGTTAATGGATCTGGTACTATGTATATAAAAAGCCTAGCTTGAGTCT180CTTTTCAGTGGCATCCTTCCCTTTCTAATCAGAGATTTTCTTCCTCAGAGATTTTGGCCT240AGATTTGCAAAATG254(2) INFORMATION FOR SEQ ID NO:28:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 504 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:MetMetThrThrSerLeuIleTrpGlyIleAlaIleAlaAlaCysCys151015CysLeuTrpLeuIleLeuGlyIleArgArgArgGlnThrGlyGluPro202530ProLeuGluAsnGlyLeuIleProTyrLeuGlyCysAlaLeuGlnPhe354045GlyAlaAsnProLeuGluPheLeuArgAlaAsnGlnArgLysHisGly505560HisValPheThrCysLysLeuMetGlyLysTyrValHisPheIleThr65707580AsnProLeuSerTyrHisLysValLeuCysHisGlyLysTyrPheAsp859095TrpLysLysPheHisPheAlaThrSerAlaLysAlaPheGlyHisArg100105110SerIleAspProMetAspGlyAsnThrThrGluAsnIleAsnAspThr115120125PheIleLysThrLeuGlnGlyHisAlaLeuAsnSerLeuThrGluSer130135140MetMetGluAsnLeuGlnArgIleMetArgProProValSerSerAsn145150155160SerLysThrAlaAlaTrpValThrGluGlyMetTyrSerPheCysTyr165170175ArgValMetPheGluAlaGlyTyrLeuThrIlePheGlyArgAspLeu180185190ThrArgArgAspThrGlnLysAlaHisIleLeuAsnAsnLeuAspAsn195200205PheLysGlnPheAspLysValPheProAlaLeuValAlaGlyLeuPro210215220IleHisMetPheArgThrAlaHisAsnAlaArgGluLysLeuAlaGlu225230235240SerLeuArgHisGluAsnLeuGlnLysArgGluSerIleSerGluLeu245250255IleSerLeuArgMetPheLeuAsnAspThrLeuSerThrPheAspAsp260265270LeuGluLysAlaLysThrHisLeuValValLeuTrpAlaSerGlnAla275280285AsnThrIleProAlaThrPheTrpSerLeuPheGlnMetIleArgAsn290295300ProGluAlaMetLysAlaAlaThrGluGluValLysArgThrLeuGlu305310315320AsnAlaGlyGlnLysValSerLeuGluGlyAsnProIleCysLeuSer325330335GlnAlaGluLeuAsnAspLeuProValLeuAspSerIleIleLysGlu340345350SerLeuArgLeuSerSerAlaSerLeuAsnIleArgThrAlaLysGlu355360365AspPheThrLeuHisLeuGluAspGlySerTyrAsnIleArgLysAsp370375380AspIleIleAlaLeuTyrProGlnLeuMetHisLeuAspProGluIle385390395400TyrProAspProLeuThrPheLysTyrAspArgTyrLeuAspGluAsn405410415GlyLysThrLysThrThrPheTyrCysAsnGlyLeuLysLeuLysTyr420425430TyrTyrMetProPheGlySerGlyAlaThrIleCysProGlyArgLeu435440445PheAlaIleHisGluIleLysGlnPheLeuIleLeuMetLeuSerTyr450455460PheGluLeuGluLeuIleGluGlyGlnAlaLysCysProProLeuAsp465470475480GlnSerArgAlaGlyLeuGlyIleLeuProProLeuAsnAspIleGlu485490495PheLysTyrLysPheLysHisLeu500(2) INFORMATION FOR SEQ ID NO:29:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 503 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:MetMetThrIleSerLeuIleTrpGlyIleAlaValLeuValSerCys151015CysIleTrpPheIleValGlyIleArgArgArgLysAlaGlyGluPro202530ProLeuGluAsnGlyLeuIleProTyrLeuGlyCysAlaLeuLysPhe354045GlySerAsnProLeuGluPheLeuArgAlaAsnGlnArgLysHisGly505560HisValPheThrCysLysLeuMetGlyLysTyrValHisPheIleThr65707580AsnSerLeuSerTyrHisLysValLeuCysHisGlyLysTyrPheAsp859095TrpLysLysPheHisTyrThrThrSerAlaLysAlaPheGlyHisArg100105110SerIleAspProAsnAspGlyAsnThrThrGluAsnIleAsnAsnThr115120125PheThrLysThrLeuGlnGlyAspAlaLeuCysSerLeuSerGluAla130135140MetMetGlnAsnLeuGlnSerValMetArgProProGlyLeuProLys145150155160SerLysSerAsnAlaTrpValThrGluGlyMetTyrAlaPheCysTyr165170175ArgValMetPheGluAlaGlyTyrLeuThrLeuPheGlyArgAspIle180185190SerLysThrAspThrGlnLysAlaLeuIleLeuAsnAsnLeuAspAsn195200205PheLysGlnPheAspGlnValPheProAlaLeuValAlaGlyLeuPro210215220IleHisLeuPheLysThrAlaHisLysAlaArgGluLysLeuAlaGlu225230235240GlyLeuLysHisLysAsnLeuCysValArgAspGlnValSerGluLeu245250255IleArgLeuArgMetPheLeuAsnAspThrLeuSerThrPheAspAsp260265270MetGluLysAlaLysThrHisLeuAlaIleLeuTrpAlaSerGlnAla275280285AsnThrIleProAlaThrPheTrpSerLeuPheGlnMetIleArgSer290295300ProGluAlaMetLysAlaAlaSerGluGluValSerGlyAlaLeuGln305310315320SerAlaGlyGlnGluLeuSerSerGlyGlySerAlaIleTyrLeuAsp325330335GlnValGlnLeuAsnAspLeuProValLeuAspSerIleIleLysGlu340345350AlaLeuArgLeuSerSerAlaSerLeuAsnIleArgThrAlaLysGlu355360365AspPheThrLeuHisLeuGluAspGlySerTyrAsnIleArgLysAsp370375380AspMetIleAlaLeuTyrProGlnLeuMetHisLeuAspProGluIle385390395400TyrProAspProLeuThrPheLysTyrAspArgTyrLeuAspGluSer405410415GlyLysAlaLysThrThrPheTyrSerAsnGlyAsnLysLeuLysCys420425430PheTyrMetProPheGlySerGlyAlaThrIleCysProGlyArgLeu435440445PheAlaValGlnGluIleLysGlnPheLeuIleLeuMetLeuSerCys450455460PheGluLeuGluPheValGluSerGlnValLysCysProProLeuAsp465470475480GlnSerArgAlaGlyLeuGlyIleLeuProProLeuHisAspIleGlu485490495PheLysTyrLysLeuLysHis500(2) INFORMATION FOR SEQ ID NO:30:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 504 amino acids(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: peptide(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:MetMetThrIleSerLeuIleTrpGlyIleAlaMetValValCysCys151015CysIleTrpValIlePheAspArgArgArgArgLysAlaGlyGluPro202530ProLeuGluAsnGlyLeuIleProTyrLeuGlyCysAlaLeuLysPhe354045GlySerAsnProLeuGluPheLeuArgAlaAsnGlnArgLysHisGly505560HisValPheThrCysLysLeuMetGlyLysTyrValHisPheIleThr65707580AsnSerLeuSerTyrHisLysValLeuCysHisGlyLysTyrPheAsp859095TrpLysLysPheHisTyrThrThrSerAlaLysAlaPheGlyHisArg100105110SerIleAspProAsnAspGlyAsnThrThrGluAsnIleAsnAsnThr115120125PheThrLysThrLeuGlnGlyAspAlaLeuHisSerLeuSerGluAla130135140MetMetGlnAsnLeuGlnPheValLeuArgProProAspLeuProLys145150155160SerLysSerAspAlaTrpValThrGluGlyMetTyrAlaPheCysTyr165170175ArgValMetPheGluAlaGlyTyrLeuThrLeuPheGlyArgAspThr180185190SerLysProAspThrGlnArgValLeuIleLeuAsnAsnLeuAsnSer195200205PheLysGlnPheAspGlnValPheProAlaLeuValAlaGlyLeuPro210215220IleHisLeuPheLysAlaAlaHisLysAlaArgGluGlnLeuAlaGlu225230235240GlyLeuLysHisGluAsnLeuSerValArgAspGlnValSerGluLeu245250255IleArgLeuArgMetPheLeuAsnAspThrLeuSerThrPheAspAsp260265270MetGluLysAlaLysThrHisLeuAlaIleLeuTrpAlaSerGlnAla275280285AsnThrIleProAlaThrPheTrpSerLeuPheGlnMetIleArgSer290295300ProAspAlaLeuArgAlaAlaSerGluGluValAsnGlyAlaLeuGln305310315320SerAlaGlyGlnLysLeuSerSerGluGlyAsnAlaIleTyrLeuAsp325330335GlnIleGlnLeuAsnAsnLeuProValLeuAspSerIleIleLysGlu340345350AlaLeuArgLeuSerSerAlaSerLeuAsnIleArgThrAlaLysGlu355360365AspPheThrLeuHisLeuGluAspGlySerTyrAsnIleArgLysAsp370375380AspIleIleAlaLeuTyrProGlnLeuMetHisLeuAspProAlaIle385390395400TyrProAspProLeuThrPheLysTyrAspArgTyrLeuAspGluAsn405410415LysLysAlaLysThrSerPheTyrSerAsnGlyAsnLysLeuLysTyr420425430PheTyrMetProPheGlySerGlyAlaThrIleCysProGlyArgLeu435440445PheAlaValGlnGluIleLysGlnPheLeuIleLeuMetLeuSerTyr450455460PheGluLeuGluLeuValGluSerHisValLysCysProProLeuAsp465470475480GlnSerArgAlaGlyLeuGlyIleLeuProProLeuAsnAspIleGlu485490495PheLysTyrLysLeuLysHisLeu500(2) INFORMATION FOR SEQ ID NO:31:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 7997 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:GAGCTCTACCCTTGCTCTGCTATTGTACTTTTTAATACACAGTTCAATCAAATGTGCCAC60CAGAATATGCATGCTAACAGCTGTAGTGGTTGATTTTTCTTTCTACTCTTCTGTGTGTAA120GACCCCATGTTTTATCAATTATTTTTTAATGATTTCTTTCTTCATGCATATGTGTGGTTG180TCAGTGTGAGTCTGTGTGTACAGCAGGTGCACAGGTATCCACAGAGGCCAGAGGTTCCCT240GTAACTAGAATTACAGGCACTTGTGAACTTTCCTGTATGGGTGCTGGGAAGCAATCTGAG300GTCTTCTGCAAGGGATCTTAACCACTGACTTTCTAGCCTGCTTTGCCCATTTCTATTTAT360GATGACTGGAAACTGGGCTTAGGCCTTATATTCTCTGAGGCCAAAATCAAGTTCTTCCAA420ACTGCAGGATTTATGGTCTTCTATAGTATCCCACAGAAATGGAAAAGAAAGTGACCCATT480AGAGCAGTATTAGAGTCGAAATAAACTCAACTTGGTATGCCAGGACTTTGGACAATAATA540ACCCTGTCTTTTCAGGGCATCTATCTGTACTGCTGCAATAGAAACTCCACAGGTCAGGGT600CACAGCTGTTGTGTTTTACACAGTGTCCCCAGGATTAGTTCAGTGCCCACCATGCAATAG660GTGTCATGGTGTGTGTGTGTGTGTGTGTGCGTGTGTCGTGCTTGTGTGCATGTGTGTGAG720ACACACACACAGAGAGATACAAAGACAGAAACAGAAAATTAATAAAATTTTACCAACTAA780AATAGGGAATTAAAGAAAAGGAGGAGAAAAAGTTGGGCATTCAACACCATAAAGTCCCAG840TACTATGCTAAGAACACCCAGCTGTCCTCACACCCGGGCATGAAACTTCATGCACTGTTC900ATCAGAAAATCGTTTACACACATCCCCTTGCAGTCTACTTGTAGTTTTAACAACTTCAGA960GAGCACTAGCATTTCCAGCCCCAGGTTAGAAGCTTTGGTAGATGCTGTTTGCGAGCACAG1020GATAGCAGCAAGAAGTGGACTTGTTAGAAGGAAAGCCAATGCCTATGTAACAACGAAAAC1080TAAGTATGAATCTCGAATCTCCACTCTCGTGTGTCTGTGTCTCCATATACGTGCTTGGGT1140GCCTGACATGGCAAGGTGTTACAAGTAAGGGAGGAACAAGAAAAGGACAGGGTAGTGGAC1200ATCAGGATGAATGCCAGCCAGGGCGACTGGAGAGAGTCTACGCTGCTCTGAAGGTGGGTG1260AAGAAGACCTCAGGAAGCTTTCTGAGGCTCCGAGAGTGCTTTTCCCTTCCCATGTTGAAA1320CATCCTTATTTGCAGAGAATTCCAGGTTCATGGGAATTTGTAAAGAGAATACTAAGAGGC1380CACCTGTGGCTTCTCCTATTTTTGTCTGCTGTCATTTATGGGACAGGGTTAGAGACCTGG1440CTTGCTTGGCTATGAGGCTGTTGCTTCCTCGGTTACTCTGCTGTGGTTGGATGCATTAGG1500GTTAGGCCCCTCAAGAGCCATGTGTCATTTTATAAAAGCAATATAAATATACTTAAGGTG1560CACAAAGCATTAGGAGGTCTGAGATAATAGATTCTGAGAAAATCTATCCTGCTGTGTAGC1620AACTGATGTTTATGATTATAGTCCCAGACCACACGATAAAGGATCTGTGGACTCTGTTTA1680GGGAGGTCAAAAAACTATTGCAAATGGAGTCTATAGAGAAAACTAGACAGGACTCAATGC1740TCACCAATCGAGAATTAGTTGATGAGCTGGGGTAGTGACTTAGTGGATAAGAACACGGTC1800CTTTCAGAGGTCCTGAGTTAAATCCCCAGCAAACACATGGTGGCTCATAACCATCTATAT1860TGTGATTTGATGCCCTCTTCTGGCATGCAGGTGTACATGCAGACTCGTATACATAAAATA1920AATAAATCTTGAAAAAATGAATACGTTGAATAAGTGTCCCCTCGGATAACTTTCTGCAGA1980ATTTTAAGCACATGTCAATGGTAATAACACACACACACACACACACACACACACACACAC2040ACACACATACACACACCATACAGATATGTATCTAGAGACATACACATGTACATTTTATCT2100CTTTTATTTTCTTCTCCCCTCTTTGACATCAAGGAATAGAATGCACTCACTGTGGCCTAG2160TGCCACACTCTACCTATTTCTTTGGCTTTACTTTGTGCTAGGTGACCCGAAAGGTTTAAA2220TATCAAAAATGCTAATGGCTCGACATTTACATCCCCAATTTCTCCTTTCTCCTTACCTCA2280GACTCTTACATTCAGTTGACAATTTGACATCGTCTCCTGGATTTTCAAATGTTCAGCACA2340CTGTACTGATGTACTGCCTTCCAAGGCAACCGGCACGATCCTCTCCCCACTCCCAAGCAT2400CCCTCCATGAGCCAGTGTTTGCTTATCTTCTTGACTCTTGTTTTAACCCAACTCCTCCCC2460TATTCACTCTGCTCTAATTCATTCATTCTATATTTTCGCACATCAGGCTCATCCTTTGCT2520CAGGAACTTCACTTTTGCTTTCCGGTCTCCTGGAAATGTGTTTTCTTGGCTATTCCATCT2580CAAGACCATCTTTTCAGAAAAGCTTTTCCTATCAACATATTTAAAGCCCTCTTCATCCCC2640CAGTAGCTCTGGACACCTCATTTTATGGATACACAACACATATTTGCCACCTGTCTCCCC2700ATTAAAATATAATCTTCAGTAGAGAAACTCCATATCTTGTTAATACCTGAAACAAGAATA2760TCTTCAAAGAGTTCCTGGGACATAAAAACGCTCAATTAATATTTATGTTAAACAGGGATC2820TGGGGTATATCACAGAGGTAGAGGGCTTACCTAGGAGGAGTTGGGCCATGGGTTCAACTT2880CCAGCACAGAATGAAAGATTATGTTAAATAAAGTTGGGAAGGATGTATGCCAGTCTATGA2940GTAGTATAGGAGGTAAATTATGAATTCATATTTACTTTTCGGACAAGAAGTGTTGTAGTC3000TTTATTTGAAATAAAATACATCTTAATTACCAATAACAATTGGTAAGGAGTGAATTCTCA3060AGCTGTGGCTTCCTGGTAGATGAGTCCTGGGAGGTTTTCTATTTCGATGATGGTAGATAG3120GTAACCTGTCATATACCACATGAAATACCTGTGGCTTTGTAAACACACCGAGCAGTCAAG3180CAGGAGAATAGTTCCATACAGTTCGCGTCCCTTAGGATTGGTTTCGGGATACTTCTGGAG3240GTTCATTTAAATAATTTTCCCCGAAGTACATTATGGGCAGCCAGTGTTGTGATGGGAAGC3300TTCTGCCTGTTTTGCTTTGCGTCGTGCTCCACACCTTTGACAGATGTGCTCTCATCTGTT3360TACTTCTTTTTCTACACACAGAGCACAGCATTAGCTGCTGTCCCGGCTTTGGATGTTATG3420TCAGCACATGAGGGACAGACCTTCAGCTTATCGAGTATTGCAGCTCTCTGTTTGTTCTGG3480AGCCTCTTCTGAGACTATGGACTTAGTTCAAGGCCGGGTAATGCTATTTTTTTCTTCTTT3540TTTCTAGTAGGAGGACAAATAGTGTTTGCTTTGGTCACTCAAGTTCAAGTTATTGGATCA3600TGGTCCTGTGCACATATAAAGTCTAGTCAGACCCACTGTTTCGGGACAGCCTTGCTTTGC3660TAGGCAAAGAGTCTCCCCTTTGGAAATTTTCCTGCTTTTGCAAAATGATGACTATTTCTT3720TGATTTGGGGAATTGCCGTGTTGGTGAGCTGTTGCATATGGTTTATTGTTGGAATAAGGA3780GAAGGTATGGAAAGATTTTTAAAAATTTGTCTTTTAGCTTATTTCTAGTATTCATTGCCT3840TCACTATTATGTAGTGCAAAAAATACTAATGCATTAATATTTTTAAATTTAAAATTTAAA3900GACGTACTTCTTTGACTAAATCTAGTAAGATGTAGAGAGTCCCCCTTGGAACATTCACAT3960ATGCCACTGGTAATGCAGATCTTGTGAAATATAACTAAAGAAATCACAAGTCATCGATGT4020AAGTTTGTGTCTGCATGGGCGGAACAAACCTAAGCTAAGAAGAGTAGTATTTGGGAGGGA4080TCTTTCTGTGACATGAACTGAATAGACGCACTGCCTCAGCAAACACACATTCATTTGAAT4140TTTCCTCAGACTCAGTCTAAGCCTGGTGAGAGCACCAAGTGTGAGTCTGTCTGCCACTAA4200CGTTTCCTTCCAGTGGTAATCAGCTGTGTGGCTGTGAAACCTTGGCGCCTGCACATGACA4260GCCATTTGAATAGTTCAAAGAACATTTAGGGACAGGATATTAAGATATTTTCTGTGATGT4320CAACATCAAAATAGGAGAATGCCCCTGGCATTATCTTCAGAGAGGTAGACTACTGTGCGT4380TGTCTTACTTTAAAGAAATTTCTTTGCCCCTTTGGCTATTTTAATTCAAACCTGAAAGTT4440TTCAGTTTTAATTAAACTGTTGATTTTCATGCTAGGAAAGGAAATATCAATTATACTTAA4500TTGTTCTTACAAGAAATAAAATCATTTATGTCGGGAGATAAATAAGCTCATAATTTTAAT4560AAAACATTTAAGAGAGAGAAAAAGAGTAGTGGATTATAGTTCATTGTCTGTCAATGTTTA4620CCTGACCCAGTTTCATTTTATAATTATCTAATTTTTCAAATGAGATTCCTGTTCTTTCCA4680AATATCATTGCAGAATACTAACATTCTTTTTTTCAGAGTTGAGAATCAAATGGAGGGTTT4740TTTCATCCTGGCACAAGCTCCGCTCTTCAGTAACACCTCCAGCCCTCAGAATGCCAATAT4800TTTAAATTATGTAGGTTGTTAAAACTTTAGTGCTGGGGCTGGGGATTTAGCTCAGTGGTA4860GAGCACTTGCCTAGCAAGCGCAAGGCCCTGGGTTCGGTCCCCAGCTCTGAAAAAAAGAAA4920AAGAAAAAAAAAAACTTTAGTGCTGTAGCCCTTTCTGTTATTTGATGTTTCACATCTGTT4980AAAAAACAAAACAAAACAAAAAAAACAAGCAAATGGAACATTTTAGGCATTCTTTGGGGG5040AAATGATTCTTAGAGCAAGTCTAATCATTAGGTGATAGTTTCATTTTTACACCAAGAACA5100AGAATCTTGTTGGCTGTGTTAACACTTTAAGCCCTGTTGTAGGGAAAAAGCAATCAGACA5160CAGGCACAGAAAAGAATTTGGATGAGTACTTGATGATGTATGTATATATGGTGAATAGAC5220TGATGGGTGGGCTGCTGGCTGGGTTGGTAAGTGGGTAGATTTTTTTTTAAAGATTTATTC5280ATTTATTATATATCAGTACACTGTAGCTATCTTCAGATACACCAGAAGGGCATCGGATCT5340CTTTACAGATGGTTGTGAGCCACCATGTTTTCCTAACCTCTCAAGTCTCTGTCTTCCAGG5400AAAGCTGGTGAACCTCCTTTGGAGAACGGGTTGATTCCGTACCTGGGCTGTGCTCTGAAA5460TTTGGATCTAATCCTCTTGAGTTCCTAAGAGCTAATCAAAGGAAGCATGGTCACGTTTTT5520ACCTGCAAACTGATGGGGAAATATGTCCATTTCATCACAAACTCCCTGTCATACCACAAA5580GTCTTATGTCATGGAAAATATTTTGACTGGAAAAAATTTCATTACACTACTTCTGCGAAG5640GTAATTAATTCGTTATACAGATTCTGTTTGTTTCCTGGTCTGTTGATGTATTAGTGTATT5700TAGTTGTTCCAATTTTGTTAGGTTGCAGAATAGAGGTAACATAAAATCAGGGCGTTTCTT5760AGTAATAAGCATTAGACATTTAAGGCAGATGTAAACCTGTCATTGATGATTCCGGAGACA5820GAGGACACTGCAGGAATCAGGAAGGTACAGATTCATAGCACCACTCGTCCCTTAACAACA5880CCCTGAGCAGGGTGTTGGCACTCTTAGCCTTCAGTCCTTGTACACACGTTTCATTCCTAA5940GATATAGGCTGTATATTTAAACACGATTTGGAAGCCATCAAGAATCTGTTCTAGAGAAAA6000CAGCATTTAATGATCTTTTGCAAGAAAATATCAGTTATAGTCTCTGTCATTAAGTACATT6060GTAATCTGGTTAAAGAGTATCTACTAAGAAAGTAAAGGCAGATTAGAACAATACCAATGG6120ATGATGGGCCATCCAGAGAAATCCTACTGTAAATGCTGGGATTTAAACTTGACCCCAAGG6180AAGAGTATGACTTGATTCTACCTTTGGAATGTGCTGTAAAATCATATTAGGGAAGGTTCC6240AGACAGAGAAGTGGGATGTATTTAATCTATCTTCCAGCCCACTCTCTAACACTAGCTAGC6300TTTGGGCTTTAGACCCTCCCCATTTCATGGATTCTATTTTCTACCAGGCATTTGGACACA6360GAAGCATTGACCCAAATGATGGAAATACCACGGAAAATATAAACAACACTTTTACCAAAA6420CCCTCCAGGGAGATGCTCTGTGTTCACTTTCTGAAGCCATGATGCAAAACCTCCAATCTG6480TCATGAGACCTCCTGGCCTTCCTAAATCAAAGAGCAATGCCTGGGTCACGGAAGGGATGT6540ATGCCTTCTGTTACCGAGTGATGTTTGAAGCCGGCTATCTAACACTGTTTGGCAGAGATA6600TTTCAAAGACAGACACACAAAAAGCACTTATTCTAAACAACCTTGACAACTTCAAACAAT6660TTGACCAAGTCTTTCCGGCACTGGTGGCAGGCCTTCCTATTCACTTGTTCAAGACCGCAC6720ATAAAGCTCGGGAAAAGCTGGCTGAGGGATTGAAGCACAAGAACCTGTGTGTGAGGGACC6780AGGTCTCTGAACTGATCCGTCTACGTATGTTTCTCAATGACACGCTCTCCACCTTTGACG6840ACATGGAGAAGGCCAAGACGCACCTCGCTATCCTCTGGGCATCTCAAGCAAACACCATTC6900CTGCAACCTTTTGGAGCTTATTTCAAATGATCAGGTAACTTTCCAGTGACAGAAATTGCA6960TTTTAAACTCAAAACCCAAAAAGACTTATAGAGCTTTCTGTGCTATCAACAAAGAAAGTA7020ATACTCAATGTCCGTGTTTAGCATGTGCGTAACAGAAGCAGCAATTTTTAGGTGCACAGT7080CCCATCGAAAGGGATGTCCCAGAAGCCACAGAACTCAGACAGGTTGGTGCTCCATTAGTA7140CAGGTTCCCTGGCCTAGTCTTGCTCCTCACCCGATATGTTCCTCTTAATATCAAATTAAA7200TCCCCGAGTGCAGTCGTCACCACCATATAAACATTTGAAATGATGACTGACTTGCAGGTG7260TGATAAGAGCAGTGACCATACCTTACTAATTCACTGGAATTCATAGGCAAAGTAACACCA7320TCGATTTTGTATTCATATAGGAGCTGCAGCCATATTTTAAATAGCACAACTACTTGTTAG7380TCAAGCATTCTGAGGCTCACTGTAATCAGGTAAAGTAGGTTTAACTCAGCGTCCTACCAG7440TTCCAGGCATTGAAATGGAATATCCTTTATCCCACCCATTCAAAACGTAATATATAAATG7500GAAGGCACAGTTTTGAAGGCCATGGTATGATTTAGGGAATTTACTCTCATGGTCCAATCC7560CTTGTAATTGTATGCTAGGTGACATATCCTTCTGACTTACTATGTTCATCGTATATTCAA7620TCCTTAGTTTATAGAGACTGACCAAAGCTCTGCTTTTGCATAGCAAAGCTCCTTTTAATG7680CCCATTCCTAAACTCAAGGACACGAATCCAGTTCAGTGCCCTTTTGCATACTCCCTGGCA7740GACTCCCGTTGCCATACATCCTCCCTCGCTCGATTCCCATGACCTCGCCCTTGCACACCC7800TGGTACTAGGACCTCTCCTGGCGATACTTCCTACTACCTATGCCACCTCATTAAAAGGAA7860GGGATAATTGCTATTTACTTGCAGTTCTCTGAATGAGGACATTTTCCCCATACGGCTCTT7920TCCACAGGAGTCCTGAAGCAATGAAAGCAGCCTCTGAAGAAGTGAGTGGAGCTTTACAGA7980GTGCTGGCCAAGAGCTC7997(2) INFORMATION FOR SEQ ID NO:32:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 5537 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:TTTTTGGTTATCTTTTCAGCCGTGCCCCACTCTACTGGTACCAGTTTACTGTATTAGTCG60ATTTTCATGCTGCTGATAAAGACATACCTGAAACTGGACAATTTACAAAAGAAAGAGGTT120TATTGGACTTACAATTCTACATCACTTGGGAGGCCTCACAATCATGATGGAAGGAGAAAG180GCACATCTCACATGGCAGCAGACAAGAAAAGAGCTTGTGCAGGGAAACTCCTCTTTTTAA240AACCATCAGATCTCATGAAATTTATTCATTATCATGACAATAGCACAGGAAAGAACTGCA300CCCATAATTCAGTCACCTCCTACCAGGTTCCTCCCACAACACGTGAGAATTCAAGATGAG360ATTTGGATGGGGACACAGCCAAACCATGTCACACTACCATGCCTGACTTCCTTTCCATTT420TTGTATATTTGCTTGTTCTTCATTTGCCCGAGAAGTAACTCTAAAGGGCTGTATTATTTG480GATATTAGATTGGCATTTTATCTGACTGGGATATCTTGCTGTGATTGTCCATGTATAAGA540TCAGCTTTTCTATAAGCCATATTTTTAAAAAGATATATTAATTTTTTAAAAATCCACCTG600TCTAAATAAATGCACAAAGCCCCCCAAAAACCTAGATTCTAAGAAAAATCTATGTACTGC660CATACAATGATTGATATTAATATTTATGGTGATAAATTACACACAAAAAATGTGTGATCT720CTGTTTAAACAGGCAAAAACAAAAAACACATGAAATAAATCTATGGCATCTATAGCCAAA780ACTGGAAACAACCCACATATCCATCAATAGGAAATCAGTTAAATAAATTATAGTACATTT840ATCCAATGGAAGATTAAGCACATATTCAATATAATTATTTATACACACATATAGATACAC900ACATGTATAAATATAGAGAATACTGTGGGTGTATGTGTGTGTGTGTTTATATACATATAT960ATACACACACAGTACTGTTGCCTACCTTCTTTTGTCTTAATTCTGTGAACTCTCATTCAC1020TCTGCTTCAGTAGGATACCTCCTTCTTTTTGGTTCTTAGACTCACCAAGTTGATCCTTGA1080CTCAAGACATTGCATTTGCTGCTTCCTCTTCCTGGAATATCCTTCCTTCTGATATTCACA1140TGAGTAGTCTCTTCTTGTCATTCAGATCTCAAATGTCACAATTTCAGAGAGCCCATCTCT1200GATCATCATATCTAAAGTTGTCCTCATTCCCCCATAGCTTTCTATACCATGTTTTATTTT1260TTTCATAACATGTATTTTATTACTCCTTTCTCCATTGGAATAGAATCTCCATTAGATTAG1320GAAATCTGCCTATCTTATTAATGCCTGCAACTGGAATACTTTTGAAGAGTTCTTGGCACG1380TAATAAATACTCAACTAATATTTTTGTGTACACAGAAATAAAGTTTGGAAGAACAGATGC1440CAAATTGTTACTAGTGGTTACTTCTGAGTAAAGGAGTAGCATGGTAGGTAAATTATTAAT1500AGATGTTCACTTTCCACCAAGATATGTTTTAGTTAGTCTTAACTTACTTGAAATGAAATT1560TATTACTTTAATAATTAGAAACATTGATAAACATTTTAGTCACAAGAATGATAGATAAAA1620TTTTGATGCTTCCAATAAGTTATATTTATCTAGAGGATGCACTTATGTAGAATACTCTCT1680TGAGGATGTTAGGTGAGTAACATGTTACTATATGTAGTAAAATATCTATGATTTTATAAA1740AGCACTGAAACATGAAGCAGCAGAAATGTTTTTCCCAGTTCTCTTTCCTCTGAACTTGAT1800CACCGTCTCTCTGGCAAAGCACCTAAATTAATTCTTCTTTAAAAGTTAACAAGACCAAAT1860TATAAGCTTGATGAATAACTCATTCTTATCTTTCTTTAAATGATTATAGTTTATGTATTT1920ATTAGCTATGCCCATCTTAAACAGGTTTATTTGTTCTTTTTACACATACCAAACTCTTAA1980TATTAGCTGTTGTCCCCAGGTCCGAATGTTAAGTCAACATATATTTGAGAGACCTTCAAC2040TTATCAAGTATTGCAGGTCTCTGATTGCTTTGGAACCACTTCTGATACCTGTGGACTTAG2100TTCAAGGCCAGTTACTACCACTTTTTTTTTTCTAATAGAATGAACAAATGGCTAATTGTT2160TGCTTTGTCAACCAAGCTCAAGTTAATGGATCTGGATACTATGTATATAAAAAGCCTAGC2220TTGAGTCTCTTTTCAGTGGCATCCTTCCCTTTCTAATCAGAGATTTTCTTCCTCAGAGAT2280TTTGGCCTAGATTTGCAAAATGATGACCACATCTTTGATTTGGGGGATTGCTATAGCAGC2340ATGCTGTTGTCTATGGCTTATTCTTGGAATTAGGAGAAGGTAAGTAATGTTTTATCTTTA2400AATTGCTCTTTGATTCATCCATTTAATTTTTTTACCTTCATTTTTATACAGTAAATTTGG2460TTTTCTATACTTACACATATTAGCATTATCTTCCTTATGTTTTAAATGAAAAATTTGATT2520TGAATTTTTAAAGTAATATCTTTTTTACTATATCTCACAAGACATATGACAGCTTCCCTT2580TTTAGTATTGGCATATACCGATGGTAATATATAAATGTATATTGGTGTTAAACATAACTG2640ACAGAAATTGTATAAGGTCTCTATGTACATTTATATGTGTATCTAAAGAGGAAGCCCAGA2700TTAGTAAGGATACAAGTAGCAAGTGGGAATCTACAATGGAAAGGATTGCTTTCTCTCACA2760TGGCTTCAATAGATACTCTTGCTTAAATAAATGTTCTCTTTTAAGCTCATTCTTGTGCAT2820CGCATAGACTCAGCCTAAGCCTGAACAAGAGCATAGAGCCTGAGCTGATCATTCTATTAC2880TGTTTTTAAATAAATGTTAATCAACTGTGGTGAATTGGGAAAGTTTGCTGAGTGTATGTG2940ACATCGATTTCATTTATTTACAACTGGTTCAAGAATGCAAGAAAAACAAATACAGTCAGA3000TCCAGAACCATAGTTTATTTAACTTCTAATTGGCTCAAGGAGTAATTGTGGGGAGGCATA3060TAGATATTCTCTGCTATGTCAATCTCAAAAAGAGAAAATAACCCTAACCATCTTTCAGCT3120TTGTAGATTGCTATGTGTTTTCTGCCTTTGCAGTTTCTTTCAGGCCTGATAGTTTTTACT3180TTTAATTAAACTACTTATCTTCAAACTAAGAAAAGAAAGGTAATTACTTTATACTGTATT3240ATTCTATCAAGAGGTACAGAAGTTTATGTTGGAAAATAAGTTTACATGTTCTAATAAAAA3300CATTTTAAAGGAGCACTGAATTACAATAGATGATTCCGTCAGTGTTTATCTTACTCAATT3360TCATTTTATAATAAGCTGATTTCTCACATGAGATTCTTCTTCTCTGAAACCATCCTTATA3420GAATATAATATAGATATCTTTAAACTAGGAATATTTTCAAAACCTCAGTTCTGAAATCCT3480CCCTTATTCAGTGATCTGTGTCTTTAAAGAAAATAATCAAAAGAAACATTTTGAGATATT3540TAGAAAAATGATGCTTAGCAAAGTGATAAACACTAGAATGTAGTTTTGTTTCCGCACTGA3600CAACAAGAATCTTGTTGGTCTTGTAAATCCTTTTGCCTGTATCACTGGGAAAAGTGATGA3660GCACATAGTAGACGGGTGCTTGTTGAATGTGTATATGGACGGATGCATGAATGGATGGAT3720TTAGTAATCCTTTCCACCAACATATCATGTTACTAGGTTAATATAACCTATTACTGTAGT3780AAAAGAGCAGGGCCCATCCAACAAAAGAAATATCTATAAACTATAGGGTTTCAAAGTTTG3840AAGTCAGTGGGAAAAATTTTAAAACCTGATGTAAGTAAAAACCCAAAACTGTAATCATCC3900ATGTCTATCATACACTTGTGTCTGACAGGCAAACGGGTGAACCACCTCTAGAGAATGGAT3960TAATTCCATACCTGGGCTGTGCTCTGCAATTTGGTGCCAATCCTCTTGAGTTCCTCAGAG4020CAAATCAAAGGAAACATGGTCATGTTTTTACCTGCAAACTAATGGGAAAATATGTCCATT4080TCATCACAAATCCCTTGTCATACCATAAGGTGTTGTGCCACGGAAAATATTTTGATTGGA4140AAAAATTTCACTTTGCTACTTCTGCGAAGGTAAGCAGTTTTACATTTATATACCATTCTG4200TTTGTCTTCTACCTTTTTATGTGCTTGTCTATTTAGAAATTTTGATGTACTTAGATTTTA4260TGATAAAGGTGTTGAAGAGAGTTATCCTTATGTGGAGATTCTTAGAAACATAAATAAATT4320ATACGTAGCTTCTTAGTAATAATCATTTAGAAAGTCAAAATAGGTATAGATTTCCGTCAT4380TTGCTTTGCACGAGCTAATGAGGGTGAAATACAGATTAAATGCTCTACTGAGACAGGTGG4440CACTGTACGAATAAGATAGATTAAAATTCATCACATCAGCAATGTCTATGCAGAGCGAAG4500TGACGGAAACCTAACATTCAGCAGTTGTCTCACCACACTTGTGCCACACAGTGTTTCATT4560TTGATAAGGAATTGGCAAGATATTTTAACATCATTTAGATGTAATAAAAGAAGATCTGTT4620ACTGAGAAAAAAAACCAATAACTACTTACTTACTGCAAATAAATATTAGCTTTGGTCTTT4680GTGACTAAGTAGCTTAAAGTTTGGTTAAAATACATCTACAGCTGGACACAATGGAACACA4740CCTGTAGTCCCTGCTATTTGAGAGGCTGAGGCAGGAGGATCGCTTGAGTCCAGGAGTTTG4800AGGCTGCAGTGAGCTATCATTGTGTCACTGCACTCCAGCCTGGGTGACAATGTGAGACCC4860CATCTCTAAAAGAAAAAGAAAAAGAAATCTACAAATAATATAAAAGATAACTAATGATTT4920TAAAACATTATCAATTAGTTTATGTGCAATAGCTGTAAATAAGTGCAGTAGCATAAGAAA4980TAAGACATAGATGACTTGAGTGATCCAGGGGAGTGCCACTGAAGTTGGCTTTAAAGGAAA5040GGTACAGTTTGGTCATTTATTTGTAAAGTGCTATGAACTTGTACAAGGGAAAGCCAATTT5100CCCGTGTTTACCAAGTAAGGAACTATGAAAGTATCTAATCCGTTTTTCAGTCATTTACTA5160TGACTAGGTCAGGTTTAACTTCTTTTTCTGCATGTTTTATTTGCTATCAGGCATTTGGGC5220ACAGAAGCATTGACCCGATGGATGGAAATACCACTGAAAACATAAACGACACTTTCATCA5280AAACCCTGCAGGGCCATGCCTTGAATTCCCTCACGGAAAGCATGATGGAAAACCTCCAAC5340GTATCATGAGACCTCCAGTCTCCTCTAACTCAAAGACCGCTGCCTGGGTGACAGAAGGGA5400TGTATTCTTTCTGCTACCGAGTGATGTTTGAAGCTGGGTATTTAACTATCTTTGGCAGAG5460ATCTTACAAGGCGGGACACACAGAAAGCACATATTCTAAACAATCTTGACAACTTCAAGC5520AATTCGACAAAGTCTTT5537(2) INFORMATION FOR SEQ ID NO:33:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 2575 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:GAATTCTACTCTTTAAAGGGGTGAATATTATGGTACTTGAATTTTATCTCAAGAAAAATG60AATAAAAAGTAACTAAATCATTGAAAATATCTGATGGCATGGGGTTTGTGGGGTAACTGG120CATTCCACAGTGATTTTCAAAGGGCTTGTGCTGTTTTCATTTTGCTTTGTTTTAGTTATG180GAGCCCTTCCTTGAAACAAACTTCATACTACAGTCCTCTTTCATGAAGCAGAAGAGGGCA240GTGGGCAGAGCTCTCCTTTGGCTTTCTCCCCCACCACAACAGGGAGCCCTGGAGCTCTAG300GAGAGAAAATCTGAAATATAAAGGGCATGCATGTGAGCTGTGGAGTCCCAGAGCCCTGGG360TTTGCATCCTAGATCTGCAACTCCCGTGAATTGAGTTTTGGGAAGTTGCTGAAACTCTGA420CCTCCTGTTTTCTCATGGTATTGTTGTAAGGGTTAAATGAGACAATGTATGTGAAGACCC480TGGCCCCACAGTAGAGGCTCTGCACACATTTCAGCGATACTTTCCTCATGTATTTCCAAA540AATGTTTTCTCATTTTCTTAAAATGTCAGAAAGAAGACAACAGAACTTACTTGCCTTTTA600CAACAGAACAAATGGAGCAAGTCAGAGGTCAAGGTGCTAACATTCTTCATGGTTCCTCAC660CACCTTTTGTTCTGTTAGCCTATAGGGAAAAGTCTTCTTTCTCATCTCATTATCTGCAGG720GGAAAATAGTACTTCAGCAAGTGATCCAGTTGAAGAACATCTCCAGGGCCATTAACATAC780AGAGGTTTGTTCTACTCTCTCTGTGCTCCATGTCTAAGAACCTCAGCCTTCCTCCTAGGA840GCTAGGGAAAGTCAGGAAAGTGAAAATAGTACCCCAGCTAATGAACTGCCCTGTGCTGGC900CTGAGAAGACAAGACCAGCTTCCTCAATGGCTCAAGATTTGGTTTCCTTCAATATGTCCT960TTTGGAAATATGTCCATGACATCGGAGAGATAAAAGGAGCCAGGATTGCTCACATTCAGG1020AAAAAAGCTCCACTATCTTTCTCTCTCTCCCTCTTTCTCTCCCTCCCCCTGACTGCCCTC1080TTCTCTATCTCTCTCTCTCCCTGAGCTGGCAAGGTTAATTGGTCGCAGAAAGCCGAAGAA1140ACAAGTGGGCCTCCTGGAACAAAGTTCAAAAAGCCGAAAACGGGAAGAAAACTAACCACA1200AAAGTAAAGGAACCACTTAGCCTTCTTTGATTCCAGGCCCCCAAGCCTGTCTTTAACTTG1260GATGAATGGAGTTCTTCCTGTGCTACAGCACCGCATAGTAGGGGCTGCCCTGGGCCTGAA1320GCCAGAGCTTCACCATATTCAGTCATCTGTACATTGAGGCAACAGTGCCTGCTTCATGGT1380GCTACCCTGTGGATTAAATGAAGCAAGTTTTTGATGATCTTGACACTGAATATTGATGCA1440TTGGTCAGACTTTTTCTGATAGTAAAAAATGGTGGTTTCTTGTTGTCAGAAATCAAATCA1500ATATATTTGTTCTCCTGTTGATTAGCTATGTCCCCTAGAGGGCAGCGACTTTGCCTGTCT1560TATTTATCTCTGCATCTCCAGCACTTAAAAGGTGCCTTGCATAAGGTACATATTAAGTTC1620ATATGAATGAATGAATGAAATGCATATGATTTATTCATACCCAGTTGGTGGTGTGTTTAC1680CCTTTCCTAAACCTGTAGTCAGATGGCCTTTGAATCCCCTGTACTTCTTGTGAGGTACTG1740TGCTGTAAAGGTGGACTATCACACTTCAGTTCAGAGCAATCTGGGCTTGAATCCTGGATT1800TGCCAGTTTATTAACTATAGCAAACATTTTTGAGCATACATTGTGCCAAGTGCTAGGCTA1860ACTGTCTTACACACATTGTCTTATTTCGTCTTAATATCTATGAGTCATGCACTATAATCA1920TCCCCATTTTACAGATAAGAAAGCAAAGACTTGGAGAGGAAAAGCATCTTGTTCAAAGGT1980AAATACTTAATGGCCAAGCCAACATGCAAATCTAGATTTAATTGCAGCTTCCTCTTCATC2040TACCATTCGAACTAATTCAAGCTATGTAATATTTCCCACTGAACCTTCTTGCCTCTACTT2100CCTCATCTTTAACATGGTCAAAATACCTGTCCTGCCCAAGTTAGTTATTTCATTAAAGTA2160GAAAAATACAAGAGAAGCTTTTAAAATGTGAAACCTCAAATGAATGTAAAATTATGATGA2220TTCCTTTAGAATTTGTCAACACCTTCTTTTCTCTACTCCTGCTAGGCATTTACAATCTCA2280AAACCATGTATTTAAGATGCAAAACTATATTTGTATTTGCCATAACTGGTTTCTTTCCCT2340ATGGCTTCATGAAAATGTGGCTCGAATGTGTTTATTATGAAAGCCCCAAATTAATCACGA2400CAAGACTTCACCAGCCCATTCCACAATAGACTCCCATTACTTTGCCCTGACTTAGAAACC2460TCATATACAGTCTTGATTCAGTACAGCTCTGTGATGCTCTTGGAAAATGCAAAGTGCTTT2520CTTAATTGAGGCAATCTGTGTCCCACTACAGAGAGGTGGTTTAACTTGTGAATTC2575(2) INFORMATION FOR SEQ ID NO:34:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 2316 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:AGAGCAACCTGGGCAACATAGCAAAACCCTGTCTCTGCAAACAATAAAAAGAAGAAAATT60AGCTGGGTATGGTGGCACATGCTATAGTCGCAGCTACTCGAGAGGTTGAGGTGGGAGGAT120CAGTTCAGCCTGGGAGGTTGAGGCTGCAGTGAGCCAGATCATGCCACTGCACTGCAGCAT180GGGCAACAGAATGAGACCCTGGCTAAAAGAAAACAAAATAAAAAATTCAGACACAGGTTG240AATCATTGATAACAGCATAGTGGTAACAGAAAGAAAGTTTGGGAAATTTTTATCTGATCA300GCTTCCCATACCCTGTTCATCTTTGTGTTATGCACTGCCAGGCTGTCTGTAGGTTCAGAC360TCTATATCATATGACCTTCAAACACTTGGTTTGTTCTTCTCCTTCCTTCCTCCCTTCTTC420TTTCATTTTTTATCTTTTTTTCTTTTAAAATGTTTAGATAGTATAATAAGGAACTGCTGA480GGCTTTCCAGTGCCTCCCTCAACATCCGGACAGCTAAGGAGGATTTCACTTTGCACCTTG540AGGACGGTTCCTACAACATCCGAAAAGATGACATCATAGCTCTTTACCCACAGTTAATGC600ACTTAGATCCAGAAATCTACCCAGACCCTTTGGTAAAGTCGCAGTGTGCCCGAATTGAAA660TTCAATATCCAGGTGATAGCTACCTAGATCTAAATAAAGAGGAAATTTACAATGGTAGAA720TTGATTTTCTCATAGTAGTCACAGGAATTGTCTGACTTAATTGTGTTAAATATTCATATA780TTTTGGAAAATTTAGATAGTGGTCTGAATTTTTCATTTTAGTCCTGATATTTGCCATCAC840ACAGTCTTTGCTAGATTATATTTGCAGTCATGATAATAAACCTGCCACTTTTTTTTTCTT900AAAAAGCACCTCCTCCCAAATCCAGGAAATTGGAGGCTAATATATTGATTATTCTAGTTT960CTTCTGGGAACCCTTCTCTCTCTAGCTCTGCCTGACTAAGGAACTAATCGTTCAAGCAGG1020ATAGGAAGGTATCACAAGGCTTCCTTAGCTGCATTAAGCTCCTGTTCCTTATTACTTTCT1080GATTCAATGTGGAGTATTTGCTAAATCACTAATGGGGTAGAATTAAAAAGAAAATTACTC1140TTTGGAGCTTCCAGGTTTAGAAAGAGATAAATTTCTTTAAAACTAGCTTAAAGGCGGTTT1200TCTTTGTATTTTTATTGCAGACTTTTAAATATGATAGGTATCTTGATGAAAACGGGAAGA1260CAAAGACTACCTTCTATTGTAATGGACTCAAGTTAAAGTATTACTACATGCCCTTTGGAT1320CGGGAGCTACAATATGTCCTGGAAGATTGTTCGCTATCCACGAAATCAAGCAATTTTTGA1380TTCTGATGCTTTCTTATTTTGAATTGGAGCTTATAGAGGGCCAAGCTAAATGTCCACCTT1440TGGACCAGTCCCGGGCAGGCTTGGGCATTTTGCCGCCATTGAATGATATTGAATTTAAAT1500ATAAATTCAAGCATTTGTGAATACATGGCTGGAATAAGAGGACACTAGATATTACAGGAC1560TGCAGAACACCCTCACCACACAGTCCCTTTGGACAAATGCATTTAGTGGTGGCACCACAC1620AGTCCCTTTGGACAAATGCATTTAGTGGTGGTAGAAATGATTCACCAGGTCCAATGTTGT1680TCACCAGTGCTTGCTTGTGAAATCTTAACATTTTGGTGACAGTTTCCAGATGCTATCACA1740GACTCTGCTAGTGAAAAGAACTAGTTTCTAGGAGCACAATAATTTGTTTTCATTTGTATA1800AGTCCATGAATGTTCATATAGCCAGGGATTGAAGTTTATTATTTTCAAAGGAAAACACCT1860TTATTTTATTTTTTTTCAAAATGAAGATACACATTACAGCCAGGTGTGGTAGCAGGCACC1920TGTAGTCTTAGCTACTCGAGAGGCCAAAGAAGGAGGATGCTTGAGCCCAGGAGTTCAAGA1980CCAGCCTGGACAGCTTAGTGAGATCCCGTCTCCAAAGAAAAGATATGTATTCTAATTGGC2040AGATTGTTTTTTCCTAAGGAAACTGCTTTATTTTTATAAAACTGCCTGACAATTATGAAA2100AAATGTTCAAATTCACGTTCTAGTGAAACTGCATTATTTGTTGACTAGATGGTGGGGTTC2160TTCGGGTGTGATCATATATCATAAAGGATATTTCAAATGTTATGATTAGTTATGTCTTTT2220AATAAAAAGGAAATATTTTTCAACTTCTTCTATATCCAAAATTCAGGGCTTTAAACATGA2280TTATCTTGATTTCCCAAAAACACTAAAGGTGGTTTT2316(2) INFORMATION FOR SEQ ID NO:35:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 10614 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:GAATTCTAAACACATATTAATATCAATGACTTATATGTATGTATATATATATCTAATATA60GATAATGTATCTAGGGATATATATATATGTATATTTTATCTTTCTTCCTTTTATTCTTTC120TTCTCCCCTCTCTGTTCAACACCGAGGAATAGAATGCACTGTGGTGTCATACTCTGCTTA180CTCAGCCTCTTATTGACCTCTGAGTCAATACAGTGCTGATGTACATCTCCAAATGCCCTC240TTTTCTCCTAACCACAGACTTTTACATTCAGTAATCAATTTGACATTGTCCCATGATTTA300CAAATGTTCACAATAGTATATTGACCTATTGCTGCCTTCCAAGGTCCTCTCCCACTCCCA360AACATCCCAATATGAACCAGCTTTTGCCTATCTTCTTGTCTCTTACTTTAACTCAATGTC420ATTCCCTATTCACTTTGCTGTAATAGATGCTACCTTGATTCTGGTTTTTAGCACCTTAAT480TTCGCTCTCTGCTCAGGAACTCTGCCTTTGCTGTTCCCTCTTCTGGGAACGCTTTTCCTT540TGCTGTTATATCTCTTCAAAACAGCTTCTCTATTCAATATGCTCAAGCTGCCTTCAGCCC600TCAACAGCTCTCCCTACCTCATTCTAGTCCCTCCACTAGAATAGAATCTTCATGAGAGTA660GCGAACTTCCCTATCTTGCTAGTACCCAAAGGCAGAAAAATCTTTAAAGAGTTCCTGGGA720CATAGAAAAAGTGCTCAATTAATATTTGTATTAAATAGGGACCTCAGGTGTAACTCCGTG780GTAGAGCGTTTGCCTTAGAGAAGTAGGGCCATGGGTTCAAATTCCAGCACAGAACAAAAA840ATTGTGCTGAATAAAGTTTGGGAGGATGTGTAGCAGTTTATAGTGCAAGTGGCATAAGCA900GTAAATAATGAATTTGTATCCACTTTTCTAGCAAGAAGTATTTTATTCTTTATTTGAAGG960ATAACAATTGGTAAAGACTGCATTCTCAAAATAAACTATGGCTTATGGCTACGTGGAAGA1020TGAGATAGGGAGAAGGTTTTTTTTTGATGATGGCAAAATAACATGTCATAGTCCACACGA1080AACACCTGTGAAGTTGTAAACACACCTAGCAATCAAACAAGAAAATTGTCCCACCCTATT1140ATCATTCTTTTGGATTGGTTGTGGCATATTTCTGGAAAATGATTTAAATTAATTCCTTCT1200AAAGGTAACAACACAAACAACCACTATCATGACGAAAAGCTTCTGCCTGTTTCAGTTTAC1260ATCATGCTCAATGTCTACAACAGACGTGCTCATCTTCAGAGTGTTTACCTCTGCTTTTTA1320CACACATTGAAGCACAATGTGAGCTGCTGTCCCTGGGTCTGAATGTTATGTCAGCACACA1380AGGGACAGAGCTTCGGCTTATCAAGTATTGAAGCTCTCTGCTTGTTTTGGAGCCTCTTCT1440GATACTATGGACTTAGTTCAAGGCTGGGCAATACTATTTTTTTCTTTTTTCTAATAGGAG1500GACAAATAGTTAGTTGTTTGCTTTGGTCATCCAAGTTCAAGTTATTGGATCATGGTCCTA1560TGTGTATAAAGAGTCTAGTTTGAGCCTTTCAGGGGCAGCCTTGCTGGCTAAGCACAGACT1620CTCCTCTTGGGAGTTTTCCTGCTTTGCAAAATGATGACCATCTCTTTGATTTGGGGGATT1680GCTATGGTAGTGTGCTGTTGTATATGGGTTATCTTTGACAGAAGGAGAAGGTATGTCTTT1740TAGCTTATTTCTAGTGTTTTCACTATTATACAGTTCCAAAAAAATACTAGTACATTAGTA1800TTTTTATTTAAAATTTAAAGCCATGCTTCTTTGACTAAACCTGACAAGATGTAGAGTTTC1860CCTTTGAATATCCACATACACTGATGGTAATGCTGATCTTGTTAAACATAACTAAAAAAA1920TTATAAGTATTGATGCATGTTTGTGTGCACTTCTGTGGAGTACACCTAAGCTGGGAAGGG1980TGCATTTGGCAAGGGTGACGTTTGGAAAGGATCTTTCTCTCACAATAACTGGTTATGCAT2040ATGCTCTTCTGGGTTCTCTGTTACATCAACATTAAAATACAGGAATACCCTTGGCATATC2100TTTGGCAAGGTAGACTGTGTCTGCTGTCTTAGTTTTAATAACTTCTTTGCCTTTTGAGTT2160ATTTGAATTTATGCCTGATCGTTTCCAGTTTTAGTTGTCTTAATGCTAAGAAAGGACAAA2220TCAATTATATTTAGTTATTCTAACAAGAGATAACTAGTTTACGTTGAAAAATAAATTATC2280TTATAATTTCTAATAAAAACATTTAAGAGAGTTAGAAATCAGCGAATTATAGCTGATGAT2340CTGCCAATGTTTACCTCACTCAACTTCATTTTAGATACTTTTTCAAGTGGGATTCCTATT2400CTCTTCAAATATCCGCACAGAATTATAGTCCCCTTCTTTCAGAGTGGGGGGAATCAAATG2460AAAGGTTTCATGTGTGCTAGGCAAGAGCACCACCGTTGAGCCACACCTCCAGACCCCACA2520ATGCCAACATTTTTAAACTATGTAGAGTTTAAAAAACTTTAGTTCTGTAGCCTTTTCTAT2580TAGCTGGTGTTTCATGTCTTCAAAGAAAAGGAAAACTGAAACATTTTAGACATATGGACA2640AATGATTCCTTGAACAAGTCTAAGCACTGATGATAGCTTCTTTTCTACAGTGAGATCAAG2700AATCTTGTTAGCCCTGTTGATACTTGTAGCCCTGTCACTTGGAAAAGCAATCAATTTTAT2760GATCTAGAAAATAGAGCTTGCCTAAAGATCAGAGTGCAGAGCTAGTCACACTAGTCAGCC2820ATACAGGTTAGGCAGTGGTGGCACATACCTTTAATCCCTGCAGCCACTCAAGTTACCCAT2880AGAAGCTGGGTGGTGGTGGTGCACACCCTTAATATAAGGTGGAGCACACTTTAATGTAAG2940GTGGGTAGAGTCAGGAGTGCAGTGTATTCAGTCTGCAGTCACACTGAGAACAATATCACC3000CCAGTCTTGTTAGAGGTAAGAACTCTCTAGTGATTGGCTGCTTTGCTCTTCTGATCTTCA3060GTTTGAACTTCTGTCTCTGGGTTTTTATTATTCGTGCTGCAGACATAGACATAGCAAACA3120ATTTAATGAGTGATTGATGAATGTAGATATGTATGTACATATTGTGCTGGATAGACTGTA3180GATGGGTTGGTGGATGGGTTGATGAGTGGGTAGATTTAGTAATCACCTTCACCAATATCT3240TAGTAGGCTAAAAAGCCCACTGTTTTAGTAAAAGAGTGGGGTATCCAACAAAGAAGTATC3300TATAAACTGTAGTTATGTGGTAGAAATAAGGGGTAGAAACCAGTAAAAATTCGGCTTATG3360TACAAATGCTAAACATGTAATTTCCTAAACCTCTCAATCTGTCTCACAGGAAAGCAGGTG3420AACCTCCTTTGGAGAATGGGTTGATTCCATACCTGGGCTGTGCTCTGAAATTTGGCTCTA3480ATCCTCTTGAGTTCCTGAGAGCAAATCAAAGAAAGCACGGTCATGTTTTTACCTGCAAAT3540TAATGGGGAAATATGTTCACTTCATCACAAACTCCTTGTCATACCATAAGGTGTTATGTC3600ATGGAAAATACTTTGATTGGAAAAAATTTCATTACACTACTTCTGCAAAGGTAACTAGTT3660TTTACAGATTTTGCTTGTTTACTAGCCTGTTTATTTATTAGTTTATTTAGTTGTTCCAAT3720GTTATTAGATTGTAGGATAAAGGGAACATAAAATCAGGAAGTCTCTTGGTACTAAGCATT3780AAAAAGTCAAGGTAAATGTGAATTTGTGATTGATGATGACATACACAAATTAAGCACTTT3840GTAAGTACTTTCTGAGCCAGAAGACACTACAGGAAGGCACAGACTCATAACATCCATGCT3900GCCATCTACACAACACTCAGAGCACTCAATTACCACATCATGCACACGAACTCGTTCGTT3960AAGAAGTCGACAGTATATTTAAGCATCATTCAGATGTTATCAAGAATCTCTATTCTAGAG4020AAAACAACACTTAGCTGAATTTTTACAAGAAAATATTAGACATGGTCTCTGTCTTAAGTA4080GATTAAAGTCTGGCTAAAGTGCATCTGCAGAGAACAAAAGGTAAAGATAAAATCAATGGC4140CCATTAGTCCAGAGAAGCTTACCTGAAAATCTGGGATTTAAACTTGACCTTAAAGGAAGA4200GTATGTCTTAAGTTTGACTTTGAAAAATGTTATGAAATTGTATTGGGAAGGCTAGACAGA4260GAAGTATGATATACTTTAATCCATCTTCCAGCCATTTCCTAACACCCAGGTTTAGCTGCT4320CCCCCTCTGACGAATTTCATTTTCTACCAGGCATTTGGACACAGAAGCATTGACCCAAAT4380GATGGAAATACCACAGAAAACATAAACAACACTTTTACCAAGACCCTCCAGGGAGATGCT4440TTGCATTCACTCTCTGAAGCCATGATGCAAAACCTTCAATTTGTTCTGAGGCCTCCTGAT4500CTTCCTAAATCAAAGAGTGATGCCTGGGTCACCGAAGGGATGTATGCCTTCTGCTACCGA4560GTGATGTTTGAAGCTGGATATCTAACTCTGTTTGGCAGGGATACTTCAAAGCCAGACACA4620CAAAGAGTGCTTATCCTGAACAACCTTAACAGCTTCAAGCAATTTGATCAAGTCTTTCCG4680GCGTTGGTGGCAGGCCTCCCTATTCACTTGTTCAAGGCGGCACATAAGGCCCGGGAACAG4740CTGGCTGAGGGCTTGAAGCATGAGAACCTCTCTGTGAGGGACCAGGTCTCGGAACTGATA4800CGTCTACGCATGTTTCTCAATGACACTCTCTCTACCTTTGATGACATGGAGAAGGCCAAG4860ACACACCTCGCTATCCTCTGGGCCTCTCAGGCAAACACTATTCCTGCAACCTTCTGGAGC4920TTATTTCAAATGATCAGGTGGATAGCAATTTGAGTGTTTATTCTTCATAGTGACAGAAAT4980TAACAATTTTTAATAAACCCCCCAAAAGACTAGCAGAGCTTTCTTTGCTGTTGGTCAAGA5040ATGTGATACTCAGTGCCTGTGTTTGACATATATATATAACAAAAGTAGCATTTTGTAAGA5100ATATAGTCTCACCAGAAAGGGATGTCCCAGAAGCCGCAGAACTTAGATCTGCTGGCACTT5160GTCATTAAAGGTCCCCTTGCCCAGTCTTGCTTTTAACTCCATAGTGTTCTTCTTAGTGTC5220AAGTTAAATCTATGACTGCAGTCTTCATCACAACTTTAAATAATGACTGACTTGTCAATG5280TGGTAAGTGCAGAGGCCACACCTTACTAGTTTGAACATTCCTGTTTTCTGCGGCCTCACA5340GATTTACAGCAGAGTTGCAACATCAATTTCATATTACCTATGAACTACAACCATATTTTA5400AGTTCAACAACTACTTGTTAGTAACATTTCTGAGGCTCAGTTCACTTTAACCAGATAAAG5460GAGATTTCAAACAGCTGCCAACAAATTTCCATGCACTGAATGGAAGTATTCTTTATCGCA5520CAGTTCAAAAATAATAACATAAATATTCTGAAGCTGTGGTATGAATTTAAAGAGTAAATT5580TGAATTTCTACTTGGGAATTCACCAATACCCTGTAATTGTATGTTAGAGGAAGTATTCGG5640AATGAATTACTCTACTCATCACACGAATGTCTAGCCCTTATTAGAATCATTGGTTTATAG5700AGATCTGACCAAAGCTTTGCTTTTACATAGCAACGCCCCTTTAATGCTTCTTCATAAATT5760CAAGGACATGAATCCAGTTCAGAATACAGTACAAGTAAATGACAATGCCCTTTGCATGTT5820CCTGGAACCACTTCCCTTTTCATGCTCCCATGCTAACGCGATCACCTCATTAAAAGAAAT5880GGAGTTCTTATTTACTTGCAGCTCTCTGAATAAGGCAATATCTTCCATATGTCTCTTTTC5940ATAGGAGTCCTGACGCATTGAGAGCAGCCTCTGAAGAAGTGAATGGAGCATTACAGAGTG6000CTGGTCAAAAGCTCAGCTCTGAAGGGAATGCAATTTATTTGGATCAAATACAACTGAACA6060ACCTGCCAGTACTAGGTGTGTTCCCTATGCTATCCCTCACTAACATGTCACTAGTAACAA6120TGCTCAACATATAATGAATGTACTATATTCTTGATATTTTTGCAACGCTGCAACAGTCTA6180ATAACTAGGGTCATCTTCATTTTTTCTAACAAACAAGGAACTGAGACCCAGAGCGTGGGA6240CAGTGGCAACCCTGGCATAGAACATTTGATACTCAGTTGCTCTAGGTCCTTGGCCTCCTT6300TCTTAGTCCTCCAAAACCACAAACCCAGGGTTAAGGAAGCATGGAATTAATGTGAACAAA6360GCAACACCATTGGTTTGGGCGATGAGACTGAGGCTTTTCTTCCTTTGTTTCTGTATTTTC6420TAGAATGCAGTAGTACCATGTATTACAGTAAAACAGCCATATTTTTGTGTCCTGTTCTGT6480AAAGGACAGAAGCCCCCATATGCTTTGAGGGCAGTTTAGTTTATTAGAAGCAACAGAGCC6540TAGATTCAGCACTGCCTGGTTTGGGACCTCCCTTTAGACACCTCCCTTTTCTCACCTGTA6600AATAAAGGCTAAGTAAGCATTTGTGACTGCATACTCAGTCATGGCCTGAATCCTGGGAAC6660AAGGCAGCTAGCAGCTAGAGGCTGGAAAACAGGACTGGACCTCAGCAGCTCTACTGCATT6720ACTTCCCCTAGAAGCAGGGTGTGGCTACACAAAACCAGACAGATAATGTATGGCTGAATG6780TAGATTCATGAAATGCTTGGAAAGACATTTACTTATCAGTATGTTTAATTCCCAAAATGG6840TCAGCAACAATTCACACAAAATTGATTATAAGTTTTTTCAATTTGCTTAGCTGTTTAGTG6900TCCAGTAGAAATAAGATTACTATTCTATAAAGTGACAGATGTTCATCTAGTTCCCATTGA6960TGGTGAAGAACATTATGTCATCCCAAAAGATCGTTAACTTAGATCGTGGTTCTCTACCTT7020CCTGATGTTGTGTGACCCCCAACTGTGAAATTATTTTCATTGCTACTTCACAACTATAAT7080TTTGCTTCTGTCATGAATCATAAAGCAAATATCTGTGTTTTCTGATGGTCTTAGGTGACC7140CCTGTGAAAGGGTCATTTGACTCTACCCCCTACATGGGTTGTGATCCACAGGTTGAGAAG7200CACTGACTTAGATTCTCAGATTGCAAGTAGAGCAGCAGAATTTCGAAGAACAGCAGTGGC7260GACAGAAGCTGCTTTGGGCAGTTGTCATTTGTTAGCTTTCATTGGCTCATTTTGTATACA7320GATTTTCGGAAGTATTTCAGACTTTATGTTATGTAGCCTTTAGAGGCAACAGTTCAGGAC7380TGGAGAGATGGCTCAAGGGTTAAGAGCACTGGCTGTTTTTTCAGAGGACCCATGTTTGAC7440TCACAGCACACACATGGTGGCTCACAGCCATCATGACTCCTGTTCCAAAGGATCTGATGT7500CTTCTTCTGACCTCTGCAGACACCAGGCATGCATACATGCAGGCAAAATACCCATCAATA7560TAAAAATAAATAACTGGGAAATATGCAAATTCTTTAATATGCAAATTCTTCTCTCCCCAA7620CTGCCATTTCCCATGCTCCACCCTCATCCCTTCCCTCCTCTCTTACTTCTTTTGTTTGGA7680ATTCTTTAGATAGCATCATCAAGGAGGCTCTGAGGCTTTCCAGTGCATCCTTGAATATCC7740GGACTGCTAAGGAGGATTTCACTCTGCACCTTGAGGATGGCTCCTATAACATCCGAAAAG7800ACGACATCATCGCTCTTTATCCACAGTTAATGCATTTGGATCCTGCAATCTACCCAGACC7860CTCTGGTAAGTTTTTCTGCTCATCAAAGTTATGTATCGAGGTGACAGTCACCCAGGAATG7920TATTTGTAATTACAGCTTTGATTTGATCATTAAAGTGAAGCCATAGGGATTGTCCCTCTT7980TATTGCGGCAAATATTCATGTTTTGGAAACTTTGGGTAGAGGCAAGAGTTTTGAACTTTT8040ACACCTAATATTCATTTCATAGTTTCTGCTAGACTATGTTTTCAGTCATAACAAAACTAC8100CACCTTTTTTCCCCCTCACAAAGTACCCTCTCCCAAATTTACACTAATGGAGGGTAATGC8160ATTTGACTTGATCCTTAGAGTAGTTGTTTAGAGCCATTTTGCTTCTTTTGTCTAACTGAA8220GAATTAGTCTACAGGTAGAACAGGAGGTCCCTAGAGCTTCTTGGTCCACCAGCTCTTCAT8280AAGCTCTTTCCAGTATCACCTGGTTCAGTGCTTGGTGTTTGCTAACTTGTAGAGGATGGA8340TTTATTAGTAGAAAATTACTCTTTGGATCCTCCAGGTCAAGAAGGCAACAACTTTCTATC8400ATAATAGCTCATTGGCTTCTTGTCTCTTTGTTGCAGACTTTTAAATATGATCGATACCTG8460GATGAGAACAAGAAGGCAAAGACCTCCTTCTATAGCAATGGAAACAAACTAAAGTATTTC8520TATATGCCATTTGGATCCGGAGCTACAATATGCCCTGGGAGACTATTTGCTGTCCAAGAA8580ATCAAGCAATTTTTGATTCTGATGCTTTCATACTTTGAACTGGAGCTTGTGGAGAGTCAT8640GTCAAGTGTCCTCCTCTAGACCAGTCCAGGGCAGGCTTGGGGATTTTGCCACCATTAAAT8700GATATTGAGTTTAAATATAAACTGAAACATCTGTGACATGTGGTTGGAAGAAGAGGACAC8760TGGATGATGTTGCTGGACTGCAGCGAGTCTCACTAAACAAGCCCTTGGGACAAATGCTCT8820CCTTTGCTTCCCAGCAACTGACTGTGCCTAGGAAAAGAACTGGTACCCCCGGCACCACTC8880TCTGTTCTCACTGCCTGAGTTCCTGGGTGTTCAGATAGCTGAGGTCAGAGTTTCACCACT8940CTTAGAAGCAATGTCTTTTGTTTTTATTTTCAAAATGAAGATACTCCAATTGGCAGATTT9000TTTTTCCTAAGGAAATTGCTTCATACTTTTATGAAAACTGATTAATTATGAAAAGGCTTC9060AAATTCACGTTTTAGTGAAACTGTTATTTTTTTCACTAGTGAAGTTCTTCATGTGTGAAC9120ATATACTATAAAAACATTTTAAGGGATCATATCATGCTTTGCATAAAGGGAAAGGAAAAT9180ATTATTCAACTTTTTTTTTTGGTTTTTCTAGACAGGGTTTCTCTGTGTAGCTTTGGAGCC9240TATCCTGGCACTCACTCTGTAGAGCAGGCTTGGTCTTGAACTCACAGAGATCTGCCTGCC9300TTTGCCTTCCGAGTGCTGGGATTAAAGTCGTGCGTCACCAATGCCTGGCTATTTAACTTT9360TTCGATGTCTAGTGGTGAGAGCTTTGAAAATGATGCTACTGTGTTGGGAATACTATGGGA9420AATTTTGATGCTTCGCTGTTACATTTAAATTTATTGCTGCTGGAAATTGTCACCCCAGTT9480TTCAATTGCCCCTCTCTCTCCCTTTTAATATTCACACTGATGAGCAGAGTTTTTTAGAGA9540TTAAAAAGACCTCCCCAGAGCCCTGTCTCTGATGTTTTTAAGCCTTTAATCTCAGTACTC9600AGGAGGCAGAGGCAGGCAGAGCTCTGTGAGTTCGAGGCCAGCCTGATCTACAGATCGAGT9660TCCAGGCAAGCCGGGGCTACAGAATGAGACCTTGTCACTAAAAGAAATAAATAAGGTCAA9720TTTTATGTCACAACTGATTATGAATCATTGTAAAGGATAAATTGAAAAAAAAGAACTCCA9780CGGGAATGACCATTTAAATGGTCTATTTTAGCTAAAATTAACTATGAATTATGTGGAGTT9840CATTAAGTGTATGTTGACGTTATATGTTCCTTTAAAATGTCTTATGTTTTATCTCTGAAT9900GTCTTGTAGATGGAGAGCAATAATAGTGTTTAAATACTGAGTCAATAAGGTTTTATCTAT9960GTACTTTAAGAGCATTATTAGCTGTGTCATTTTTACTGATATATCTAATATATTTATATG10020TAAATTATATTTATCTTTTATCTTATACTACAAATATAAGTAAATATTTTAAAACCAGTA10080ACTTTAAAATTACCTACCTTTCAGAAATGAAAATAAGAACATTTGTGCTTTAACCTTTGA10140AATAGAATGTTTATTCATCCACTGATAAGTTAAAATAATTTTATCTGATTTGTTTCAAGA10200AACTCAAAAATATTCAAAGTAATCATGCACTCAAAGGTCTTCGTAAGGTTACAGAAAATT10260CAATAAAATCTTTTTTGTGTAGGGACTGAGTCAGGGTCTAGAAGATGCTTGGCAGGTACT10320CCAGTAGTGAGCTGGATCCAGAAGATTCCTTAAACTTTAAAATCTTAACACTAAGTATTA10380TCACAGAGTTATTACCTAAGTAGAATATTTTTCCTTTCCTTTTCAATTGACAGAGTCCCA10440CAGCAACACAGCTGGCTGTAACTCTTCACATAGCTTGCGCAGGCTTTGAACTCACTGTAC10500TCCTGCCTTTCCTTTTCTAGGAAATTATTTTCCACATCAAGAAAATTTAATTGTTCCGAT10560GAGGTATAGAGTAACAAATTTCTGTTATATATTCATCTGTATTAAACTGAATTC10614(2) INFORMATION FOR SEQ ID NO:36:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 12 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:TCAAGTTCAAGT12(2) INFORMATION FOR SEQ ID NO:37:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 12 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:CCAAGCTCAAGT12__________________________________________________________________________

Claims

1. A culture of HepG2 cells transfected with CYP7 DNA that is regulatory with respect to CYP7 expression in the presence of bile acids, wherein

(a) said culture is confluent, and

(b) said culture is responsive to the presence of bile acids.

2. A culture according to claim 1, wherein said culture is matured to at least about 4 days prior to initiation of transfection.

3. A culture according to claim 1, wherein said CYP7 DNA comprises a fragment of human CYP7 from a region between about -223 to about +32, measured relative to the transcription start site, +1.

4. A culture according to claim 3, wherein said human CYP7 DNA fragment is selected from DNA fragments in the group consisting of from about -104 to about -30, from about -78 to about -36, from about -159 to about -124, from about -147 to about -128, from about -169 to about -152, from about -104 to about -79, from about -71 to about -54 and from about -89 to about -68, measured relative to the transcription start site, +1.

5. A culture according to claim 1, wherein the CYP7 DNA comprises a fragment of rat CYP7 from a region between about -224 to about +32, measured relative to the transcription start site, +1.

6. A culture according to claim 1, wherein said cells are transfected with a construct comprising said CYP7 DNA and a reporter molecule that is capable of indicating regulatory activity of said CYP7 DNA.

7. A culture according to claim 6, wherein said reporter molecule is non-CYP7 DNA.

8. A culture according to claim 7, wherein said non-CYP7 DNA encodes luciferase.

9. A method for determining an agent's effect on CYP7 DNA comprising the steps of:

(a) bringing into contact with an agent, a culture of HepG2 cells transfected with CYP7 DNA that is regulatory with respect to bile acids, wherein

(i) said culture is confluent, and

(ii) said culture is responsive to the presence of bile acids, and

(b) determining whether said agent inhibits or stimulates the regulatory activity of said CYP7 DNA.

10. A method according to claim 9, wherein said culture is matured for at least about 4 days prior to the initiation of transfection.

11. A method according to claim 9, wherein said CYP7 DNA comprises a fragment of human CYP7 from a region between about -223 to about +32, measured relative to the transcription start site, +1.

12. A method according to claim 11, wherein said human CYP7 DNA fragment is selected from DNA fragments in the group consisting of from about -104 to about -30, from about -78 to about -36, from about -159 to about -124, from about -147 to about -128, from about -169 to about -152, from about -104 to about -79, from about -71 to about -54 and from about -89 to about -68, measured relative to the transcription start site, +1.

13. A method according to claim 9, wherein the CYP7 DNA comprises a fragment of rat CYP7 from a region between about -224 to about +32, measured relative to the transcription start site, +1.

14. A method according to claim 9, wherein in step (a), a reporter molecule is operatively linked to said CYP7 DNA, and wherein in step (b) said determining comprises monitoring the expression of said reporter molecule.

15. A method according to claim 14, wherein said reporter molecule is non-CYP7 DNA that is operatively linked to said CYP7 DNA, and wherein said determining comprises monitoring the expression of a protein encoded by said non-CYP7 DNA.

16. A method according to claim 15, wherein said non-CYP7 DNA encodes the protein luciferase.

17. A method according to claim 9, wherein said agent is a physiological agent endogenous to a human.

18. A method according to claim 9, wherein said agent is an agent exogenous to a human.

19. A method of obtaining a culture of HepG2 cells responsive to the presence of bile acids, comprising:

(a) transfecting a culture of HepG2 cells with CYP7 DNA having a bile acid responsive element; and

(b) culturing said culture to substantially complete confluency such that said culture is capable of responding to the presence of bile acids.

20. A method according to claim 19, wherein said culture is matured to at least about 4 days prior to initiation of transfection.

21. A method according to claim 19, wherein said CYP7 DNA comprises a fragment of human CYP7 from a region between about -223 to about +32, measured relative to the transcription start site, +1.

22. A method according to claim 21, wherein said human CYP7 DNA fragment is selected from DNA fragments in the group consisting of from about -104 to about -30, from about -78 to about -36, from about -159 to about -124, from about -147 to about -128, from about -169 to about -152, from about -104 to about -79, from about -71 to about -54 and from about -89 to about -68, measured relative to the transcription start site, +1.

23. A method according to claim 19, wherein the CYP7 DNA comprises a fragment of rat CYP7 from a region between about -224 to about +32, measured relative to the transcription start site, +1.

24. A method according to claim 19, wherein said cells are transfected with a construct comprising said CYP7 DNA and a reporter molecule that is capable of indicating regulatory activity of said CYP7 DNA.

25. A method according to claim 24, wherein said reporter molecule is non-CYP7 DNA.

26. A culture according to claim 25, wherein said non-CYP7 DNA encodes luciferase.